An endogenous lipid mediator for neuroinflammation and chronic pain — mechanism, trial data, and where it belongs in an integrative plan Yoon Hang Kim, MD, MPH Board-Certified in Preventive Medicine | Integrative & Functional Medicine Physician Most supplements marketed for pain have a story but no trial data. Palmitoylethanolamide is unusual: it has both. It is a molecule the human body already makes, it has a defined nuclear receptor target, and it has now been through more than a dozen randomized controlled trials and four independent meta-analyses. That is a stronger evidence base than several agents I am routinely asked to comment on — and it is still thin enough that the honest answer involves real caveats. This article walks through what PEA is, how it works, what the controlled trials show (including the ones that failed), and how I think about it when a client with chronic pain or suspected neuroinflammation sits in front of me. What PEA Actually Is Palmitoylethanolamide is an N-acylethanolamine — the amide of palmitic acid and ethanolamine — produced on demand by cells in response to injury and inflammatory stress. It is present in human tissue, in breast milk, and in ordinary foods such as egg yolk, soybeans, and peanuts. It was first studied in the 1950s as an anti-inflammatory fraction of egg yolk, and it has been available in Europe for years as a food for special medical purposes. Two points matter for framing. First, PEA is not a cannabinoid in the way people assume. It is structurally related to endocannabinoids and is often lumped in with them, but it is not a meaningful direct agonist at CB1 or CB2, and it is not psychoactive. Second, PEA is not an analgesic in the NSAID or gabapentinoid sense. It does not block a pain signal acutely. It modulates the non-neuronal cells — mast cells, microglia, astrocytes — that keep a pain signal amplified. That distinction explains almost everything about how it behaves clinically, including why it takes weeks to work. Mechanism: Resolution Rather Than Suppression The clearest mechanistic finding came from Piomelli’s group in 2005, which identified the nuclear receptor PPAR-α as the molecular target responsible for PEA’s anti-inflammatory effects. PEA activated PPAR-α in vitro and reduced inflammation in wild-type mice, but had no effect in mice lacking PPAR-α — a clean genetic demonstration rather than a correlation.1 Later work confirmed that PPAR-α also mediates PEA’s acute effects on sensory neurons.2 Downstream of PPAR-α activation, PEA restrains NF-κB-driven transcription of pro-inflammatory mediators, stabilizes mast cells, and dampens microglial activation. Skaper and colleagues framed this as a strategy of resolution — supporting the body’s own mechanism for shutting an inflammatory response down — rather than blocking a single enzyme or receptor.3,4 This is also the basis of the older ALIA concept (autacoid local injury antagonism): a locally produced signal that rises after tissue insult and helps return the system to baseline. A secondary, less firmly established mechanism is the so-called entourage effect: PEA appears to indirectly increase anandamide tone and to desensitize TRPV1 channels. This is biologically plausible and supported by preclinical work, but it should be presented as hypothesis rather than established human pharmacology. If central sensitization and glial activation are driving a client’s pain, PEA is aimed at the right target. If the pain is purely mechanical and structural, the mechanism gives less reason to expect benefit. The Clinical Evidence The meta-analytic signal Four meta-analyses have now been published, and they agree in direction while disagreeing in magnitude. Artukoglu et al. (2017) published the first meta-analysis of PEA for pain, concluding that PEA reduced pain scores relative to control.5 Paladini et al. (2016) pooled raw data from controlled and open-label trials of micronized and ultra-micronized PEA. By day 60, 81% of PEA-treated participants had reached a pain score of 3 or below, compared with 40.9% of controls. The effect was independent of age, sex, and pain etiology.6 Lang-Illievich et al. (2023) restricted inclusion to double-blind RCTs — 11 trials, 774 participants — and found a pooled standardized mean difference of 1.68 (95% CI 1.05 to 2.31), with several trials also reporting improved function and quality of life and no significant adverse effects.7 A 2025 meta-analysis in Nutrition Reviews (18 studies, 1,196 participants) found significant pain reduction at 6 weeks, 8 weeks, and 24–26 weeks, with benefit across all three pain phenotypes: nociceptive, neuropathic, and nociplastic.8 An effect size near 1.0 or above is large for an analgesic — larger than most pain pharmacotherapy — and that should trigger appropriate skepticism. The included trials are small, heterogeneous in condition and outcome measure, and heavily weighted toward research groups and industry with a stake in the compound. The direction of effect is consistent and replicated; the precise magnitude is probably inflated. Knee osteoarthritis Steels and colleagues randomized 111 adults with mild-to-moderate knee osteoarthritis to 300 mg PEA, 600 mg PEA, or placebo daily for 8 weeks. Both active arms showed significant reductions in total WOMAC score (300 mg, p = 0.0372; 600 mg, p = 0.0012), with a dose-dependent pattern and improvements in secondary anxiety and sleep measures.9 This trial is important for a second reason discussed below: it used non-micronized PEA. Diabetic peripheral neuropathy Pickering and colleagues conducted a quadruple-blinded, placebo-controlled trial of 600 mg PEA daily for 8 weeks in 70 adults with type 1 or type 2 diabetes and painful peripheral neuropathy. They found significant reductions in Brief Pain Inventory total pain and pain interference and in NPSI total and sub-scores — with the notable exception of evoked pain (p = 0.09). Sleep quality improved, IL-6 and CRP fell, and 94% of participants completed the study.10 The evoked-pain result is the interesting one. It is consistent with the mechanistic story: PEA appears to act on the tonic, inflammation-driven component of neuropathic pain rather than on stimulus-evoked allodynia. Where PEA failed Any honest review has to include Andresen et al. (2016), published in Pain. Seventy-three individuals with spinal cord injury neuropathic pain received ultra-micronized PEA or placebo as add-on therapy for 12 weeks. There was no effect on the primary outcome.11 This is the most methodologically rigorous negative trial in the literature, and it is instructive rather than disqualifying. Established central neuropathic pain following long-standing cord injury is a different problem from active peripheral neuroinflammation — a point made directly in the published commentary on that trial. PEA is a resolution agent. It has the best chance where an inflammatory process is still running, and the least where the nervous system has already been structurally rewired. The Formulation Question Marketing in this space is emphatic that only micronized or ultra-micronized PEA works. The reasoning is real: PEA is lipophilic and poorly water soluble, and particle-size reduction improves dissolution and oral absorption. Preclinical work has shown micronized and ultra-micronized PEA to be superior to non-micronized PEA in a rat inflammatory pain model.12 The human data are less tidy. The Steels osteoarthritis trial and the Pickering neuropathy trial both used non-micronized or alternative-delivery formulations and both were positive, which the authors of the 2023 meta-analysis noted as an argument against micronization being strictly necessary in humans.7,9,10 Meanwhile, the negative spinal cord injury trial used the ultra-micronized product.11 My reading: particle size and delivery clearly influence bioavailability, but formulation is not the variable that separates responders from non-responders in the current human literature. Manufacturing quality, verified content, and third-party testing are the more defensible things to insist on. Dosing and Time Course Trial regimens have clustered narrowly. Most positive studies used 600 mg daily, given either as a single dose or as 300 mg twice daily, with some protocols using 1,200 mg daily during an initial loading phase before stepping down. Both 300 mg and 600 mg daily produced benefit in the osteoarthritis trial, with the higher dose performing better.9 Timeline matters more than dose, and it is the single most common reason for a false negative in practice. Meaningful separation from placebo generally appears between 4 and 8 weeks.8 A client who takes PEA for ten days, feels nothing, and stops has not actually tested it. I tell people at the outset to commit to a defined trial and to score their pain at baseline, so the decision to continue or stop is made on data rather than impression. A 2024 systematic review of extended treatment supports durability of benefit beyond the typical 8-week window.13 Safety and Tolerability This is where PEA has its clearest advantage, and it is worth stating precisely rather than as “well tolerated.” Gabrielsson, Mattsson, and Fowler examined the safety literature critically — including the trials that reported it poorly — and concluded that for treatment durations up to 49 days, the available data argue against serious adverse drug reactions at an incidence of 1 in 200 or greater. For treatment beyond 60 days, the number of exposed participants is insufficient to rule out reactions at a rate below 1 in 100.14 That is a genuinely favorable profile with an honest boundary attached. Reported adverse effects are uncommon and mild, mostly gastrointestinal. No clinically significant drug–drug interactions have been documented, which is what makes PEA usable alongside conventional analgesics rather than in place of them. The realistic limitation is long-term safety data, not short-term risk. Where PEA Fits in an Integrative Plan I consider PEA when one or more of the following is true: NSAIDs are unavailable or unwise — chronic kidney disease, GI bleeding risk, anticoagulation, cardiovascular risk, or simply a client who has been on daily NSAIDs for years and needs an exit strategy. The clinical picture suggests neuroinflammation or central sensitization — pain out of proportion to imaging, widespread rather than localized symptoms, poor sleep, cognitive fog, flares tracking with immune activation. Mast cell activation is part of the picture. PEA’s mast-cell-stabilizing mechanism makes it mechanistically attractive here, though I want to be clear that MCAS-specific controlled trial data for PEA do not yet exist. This is mechanism-based reasoning, not proven efficacy. An additive, low-risk layer is needed alongside an existing regimen — including alongside low-dose naltrexone, where the glial-modulating rationale overlaps but the targets differ. What PEA is not: a rescue analgesic, a replacement for addressing the driver of the pain, or a reason to skip a structural workup. The most common clinical error I see is adding PEA to an unexamined problem and calling that a treatment plan. What We Still Do Not Know Trial size and independence. Most studies are small and single-center, and a substantial share come from groups connected to manufacturers. Large, independent, multicenter replication has not happened. Who responds. No validated predictor identifies likely responders in advance. Response appears to be roughly even odds, with a subset reporting substantial relief. Beyond pain. Signals for mood, sleep, cognition, and post-viral symptoms are mechanistically coherent and preliminary. They should not be presented to clients at the same confidence level as the chronic pain data. Long-term use. Reassuring short-term safety does not establish multi-year safety. The Clinical Bottom Line PEA is one of the better-supported non-pharmaceutical options for chronic and neuropathic pain: a defined mechanism, replicated positive RCTs across four meta-analyses, a favorable short-term safety profile, and no meaningful interaction burden. It is also modest in effect for many people, unproven in several of the conditions it is marketed for, and useless if stopped at two weeks. Given that risk–benefit ratio, an 8-week structured trial at 600 mg daily with baseline and follow-up pain scoring is a reasonable thing to consider for the right client — as one layer of a plan, not as the plan. Important: This article is educational and is not medical advice. It does not establish a physician–client relationship and is not a substitute for individualized evaluation. Supplements can interact with medications and are not appropriate for everyone, including during pregnancy and lactation. Do not start, stop, or change any treatment based on this article. Please discuss any therapy described here with your own licensed clinician before making a decision. References Lo Verme J, Fu J, Astarita G, et al. The nuclear receptor peroxisome proliferator-activated receptor-alpha mediates the anti-inflammatory actions of palmitoylethanolamide. Mol Pharmacol. 2005;67(1):15-19. doi:10.1124/mol.104.006353. PMID: 15465922. Khasabova IA, Xiong Y, Coicou LG, et al. Peroxisome proliferator-activated receptor α mediates acute effects of palmitoylethanolamide on sensory neurons. J Neurosci. 2012;32(37):12735-12743. Skaper SD, Facci L, Giusti P. N-palmitoylethanolamine and neuroinflammation: a novel therapeutic strategy of resolution. Mol Neurobiol. 2015;52(2):1034-1042. Skaper SD, Facci L, Fusco M, et al. Palmitoylethanolamide, a naturally-occurring disease-modifying agent in neuropathic pain. Inflammopharmacology. 2014;22(2):79-94. Artukoglu BB, Beyer C, Zuloff-Shani A, Brener E, Bloch MH. Efficacy of palmitoylethanolamide for pain: a meta-analysis. Pain Physician. 2017;20(5):353-362. PMID: 28727699. Paladini A, Fusco M, Cenacchi T, Schievano C, Piroli A, Varrassi G. Palmitoylethanolamide, a special food for medical purposes, in the treatment of chronic pain: a pooled data meta-analysis. Pain Physician. 2016;19(2):11-24. PMID: 26815246. Lang-Illievich K, Klivinyi C, Lasser C, Brenna CTA, Szilagyi IS, Bornemann-Cimenti H. Palmitoylethanolamide in the treatment of chronic pain: a systematic review and meta-analysis of double-blind randomized controlled trials. Nutrients. 2023;15(6):1350. doi:10.3390/nu15061350. PMID: 36986081. Meta-analysis of palmitoylethanolamide in pain management: addressing literature gaps and enhancing understanding. Nutr Rev. 2025;83(7):e1604. PMID: 39798151. [Author list to be confirmed before publication.] Steels E, Venkatesh R, Steels E, Vitetta G, Vitetta L. A double-blind randomized placebo controlled study assessing safety, tolerability and efficacy of palmitoylethanolamide for symptoms of knee osteoarthritis. Inflammopharmacology. 2019;27(3):475-485. doi:10.1007/s10787-019-00582-9. Pickering E, Steels EL, Steadman KJ, Rao A, Vitetta L. A randomized controlled trial assessing the safety and efficacy of palmitoylethanolamide for treating diabetic-related peripheral neuropathic pain. Inflammopharmacology. 2022;30(6):2063-2077. doi:10.1007/s10787-022-01033-8. PMID: 36057884. Andresen SR, Bing J, Hansen RM, et al. Ultramicronized palmitoylethanolamide in spinal cord injury neuropathic pain: a randomized, double-blind, placebo-controlled trial. Pain. 2016;157(9):2097-2103. doi:10.1097/j.pain.0000000000000623. PMID: 27227691. Impellizzeri D, Bruschetta G, Cordaro M, et al. Micronized/ultramicronized palmitoylethanolamide displays superior oral efficacy compared to nonmicronized palmitoylethanolamide in a rat model of inflammatory pain. J Neuroinflammation. 2014;11:136. doi:10.1186/s12974-014-0136-0. PMID: 25164769. Schweiger V, Schievano C, Martini A, et al. Extended treatment with micron-size oral palmitoylethanolamide (PEA) in chronic pain: a systematic review and meta-analysis. Nutrients. 2024;16(11):1653. doi:10.3390/nu16111653. PMID: 38892586. Gabrielsson L, Mattsson S, Fowler CJ. Palmitoylethanolamide for the treatment of pain: pharmacokinetics, safety and efficacy. Br J Clin Pharmacol. 2016;82(4):932-942. doi:10.1111/bcp.13020. PMID: 27220803. D’Amico R, Impellizzeri D, Cuzzocrea S, Di Paola R. ALIAmides update: palmitoylethanolamide and its formulations on management of peripheral neuropathic pain. Int J Mol Sci. 2020;21(15):5330. doi:10.3390/ijms21155330. PMID: 32727084. Polati E, Martini A, Schweiger V. Ultramicronized palmitoylethanolamide treatment in central neuropathic pain following longstanding spinal cord injury: try to extinguish the fire after everything was burned. Pain. 2017;158(4):763-764. PMID: 28301405. About Dr. Kim Yoon Hang Kim, MD, MPH is a board-certified physician with more than 20 years of clinical experience. He completed a fellowship at the University of Arizona under Dr. Andrew Weil and holds board certification in Preventive Medicine along with certifications in medical acupuncture and integrative and holistic medicine. His clinical focus includes low dose naltrexone (LDN), autoimmune conditions, chronic pain, integrative oncology, fibromyalgia, chronic fatigue syndrome, mast cell activation syndrome (MCAS), and mold toxicity. He is the author of four books and more than 20 peer-reviewed articles, including MCAS: Epidemic in Plain Sight and LDN Primer, both available on Amazon. He is also the founder of the LDN Support Group. Yoon Hang Kim, MD, MPH | Board-Certified in Preventive Medicine | Integrative & Functional Medicine Physician Professional: www.yoonhangkim.com | Clinical: www.directintegrativecare.com

Association Is Not Causation Looking Deeper into the Melatonin–Heart Failure Study Yoon Hang Kim, MD, MPH Board-Certified in Preventive Medicine | Integrative & Functional Medicine Physician Meet Yoon Hang Kim MD Important: This article is intended for educational and informational purposes only. It does not constitute medical advice, diagnosis, or treatment. Always consult your physician or qualified healthcare provider before making changes to your supplement regimen. The Headline vs. the Evidence If you follow health news, you may have seen some alarming headlines recently: "Melatonin linked to heart failure." For many of my clients — people who rely on melatonin as a safe, non-habit-forming sleep aid — this kind of headline is genuinely unsettling. But as is so often the case, what the study actually found and what the headline implies are two very different things. Let's walk through what this research really showed, where its limitations lie, and what it means for you practically. What the Study Actually Found The analysis in question was a retrospective electronic health record (EHR) cohort study presented as an abstract at an American Heart Association (AHA) scientific session. The researchers used a large database called TriNetX to compare people who had documented long-term melatonin use against those who did not. After propensity-score matching — a statistical technique designed to make the two groups more comparable on recorded characteristics — they found that the melatonin group had a higher incidence of heart failure over five years: roughly 5% versus 3%, with a hazard ratio of 1.89. That is a real statistical association. It is not evidence that melatonin caused heart failure. The distinction matters enormously — and it is the single most important thing to understand about this study. Why Association Is Not Causation In epidemiology, we learn early that observing two things happening together does not tell us that one caused the other. The classic example: ice cream sales and drowning rates both rise in summer. Ice cream does not cause drowning. A shared factor — warm weather — drives both. This same logic applies here. Propensity matching can adjust for measured variables: age, sex, comorbidities, medications, lab values, and healthcare utilization patterns. That is valuable, and to the researchers' credit, the association persisted even under a stricter prescription-fill definition. But matching cannot account for what it cannot see. The Confounders Hiding in Plain Sight The most significant concern is what epidemiologists call confounding by indication — the idea that the very reason someone takes melatonin long-term may itself be the thing that raises their heart failure risk. Think about who uses melatonin chronically. These are often people dealing with: Severe, treatment-resistant insomnia Anxiety or depression Chronic pain syndromes Shift-work schedules that disrupt circadian rhythm Undiagnosed or undertreated sleep apnea Neurocognitive conditions General frailty or aging-related sleep disruption Every single one of these conditions is independently associated with cardiovascular risk. If the melatonin group was enriched for these burdens — and it almost certainly was, because those are the reasons people take melatonin long-term — then the heart failure signal may reflect the underlying conditions, not the supplement. Other Limitations Worth Knowing Exposure misclassification. Melatonin is available over the counter. Many people in the "non-user" group may have been taking it — they just never told their doctor. The study could not capture dose, formulation, timing, or adherence with any precision. When you cannot clearly define who is actually exposed and who is not, your results become unreliable. Reverse causation. Heart failure does not appear overnight. In its early, undiagnosed stages, it can cause fluid retention, nocturnal dyspnea, and disrupted sleep — all of which might lead someone to start taking melatonin. In that case, melatonin use would be a marker of evolving heart disease rather than a cause of it. Outcome validity. The heart failure "outcome" was an ICD billing code in an EHR. These codes are used for administrative purposes and are not the same as independently verified, clinician-adjudicated diagnoses. The particularly striking difference in heart failure hospitalizations between groups raises questions about whether the groups had different baseline vulnerabilities or different patterns of healthcare contact. Abstract-level evidence. This was a conference presentation, not a published peer-reviewed manuscript. The full methods, covariate definitions, missing-data handling, and subgroup analyses have not yet been subjected to formal peer scrutiny. What Would It Take to Prove Causation? If researchers want to move beyond association, the next logical step would be a well-designed prospective cohort study: enroll people when they first start melatonin, compare them to clinically similar people starting a different sleep strategy, measure dose and adherence carefully, account for sleep apnea and insomnia severity, and follow them forward with independently verified heart failure outcomes. The gold standard would be a randomized controlled trial — melatonin versus placebo in a defined insomnia population, with blinded, adjudicated outcomes. Randomization handles both measured and unmeasured confounding. But heart failure events are uncommon enough that such a trial would need to be very large and very long, making it expensive and logistically challenging. Until that work is done, this study gives us a safety signal. It does not give us a conclusion. What This Means for You If you are my client and you take melatonin, this study is not a reason to panic. But it is a reasonable prompt to reflect on a few things: Why are you taking it? If the answer is "I've been taking it for years and never questioned it," that deserves a conversation. Chronic supplement use without periodic reassessment is common, and it is worth revisiting the rationale. Have underlying sleep issues been addressed? If melatonin is masking untreated sleep apnea, anxiety, or circadian disruption, the right move is to address the root cause — not simply add a nightly supplement indefinitely. Dose and duration matter. Most over-the-counter melatonin is dosed far higher than what the body produces physiologically. Working with a knowledgeable clinician to find the lowest effective dose — or to explore whether you still need it at all — is prudent. Melatonin remains, by the available evidence, one of the safest sleep-supporting supplements. This study does not change that conclusion — but it does remind us that no supplement should be taken on autopilot forever. The Right Question to Ask A good way to think critically about studies like this is to ask: What characteristic could lead someone to use melatonin long-term AND independently raise their risk of heart failure — even after the statistical adjustments? If you can think of even one plausible answer (and we listed several above), then you have identified a reason to be cautious about drawing causal conclusions from this data. Headlines are designed to get clicks. Your health decisions deserve more nuance than a headline can offer. About Dr. Kim Yoon Hang Kim, MD, MPH, is board-certified in Preventive Medicine with over 20 years of experience in integrative and functional medicine. A graduate of the University of Arizona Center for Integrative Medicine's prestigious Osher Fellowship under Dr. Andrew Weil, Dr. Kim holds certifications in preventive medicine, medical acupuncture, and integrative and functional medicine. He specializes in low-dose naltrexone (LDN), autoimmune conditions, chronic pain, integrative oncology, fibromyalgia, chronic fatigue syndrome, mast cell activation syndrome (MCAS), and mold-related illness. Dr. Kim is the author of MCAS: Epidemic in Plain Sight and LDN Primer, both available on Amazon, and the founder of the LDN Support Group. He has published over 20 peer-reviewed articles and authored multiple clinical texts on integrative approaches. Professional: www.yoonhangkim.com | Clinical: www.directintegrativecare.com

By Yoon Hang "John" Kim, MD, MPH — Board-Certified Preventive Medicine Physician specializing in Integrative and Functional Medicine | www.directintegrativecare.com Abstract Creatine monohydrate is one of the most extensively studied dietary supplements available, with over three decades of clinical trial data supporting its role in improving strength, lean mass, and high-intensity exercise capacity. Despite this, confusion between creatine (the supplement) and creatinine (its metabolic waste product) continues to cause unnecessary alarm when routine kidney labs come back looking “off.” This article explains the difference between the two molecules, reviews what the evidence — including 2025–2026 meta-analyses — actually supports regarding muscle performance, cognitive function, and kidney safety, and offers practical guidance on dosing, product selection, and when to involve your physician. Recent data confirm that creatine supplementation modestly raises serum creatinine (approximately 0.13–0.14 mg/dL on average) without corresponding changes in directly measured kidney filtration, reinforcing that this is a lab artifact rather than evidence of kidney injury in healthy individuals. The goal is simple: help you understand what creatine does, what it does not do, and how to have a smarter conversation with your clinician about what your labs actually mean. Patients ask about creatine more often now than they did five years ago. It used to live almost entirely in the gym conversation. It now shows up in conversations about aging muscle, brain fog after poor sleep, plant-based diets, and "my creatinine came back high and my doctor is worried." That last sentence is why this article exists. Creatine and creatinine sound like the same molecule with a typo. They are not. Confusing them leads people to stop a useful supplement — or, worse, to ignore a real kidney problem because "it's just the creatine." Both mistakes are avoidable. This is educational, not a prescription. If you have kidney disease, take medications that affect the kidneys, or you are pregnant or breastfeeding, talk with your own clinician before you start anything. Creatine and Creatinine Are Related — They Are Not Interchangeable Creatine is a compound your body makes from three amino acids: arginine, glycine, and methionine. About 95% of body creatine is stored in skeletal muscle, with roughly two-thirds present as phosphocreatine. When you need a fast burst of energy — a heavy lift, a sprint, standing up quickly as you get older — phosphocreatine donates a phosphate group to regenerate ATP. Your liver, kidneys, and pancreas make about 1 gram a day. A typical omnivorous diet adds another 1–2 grams from meat and fish. Muscle stores sit about 60–80% full on diet alone. Supplementation can raise those stores another 20–40%. Creatinine is the waste product. Every day, roughly 1–2% of your muscle creatine pool spontaneously breaks down into creatinine. The kidneys filter it. That is why serum creatinine (and the eGFR calculated from it) became a routine kidney marker. A simple way to remember it: Creatine is the fuel. Creatinine is the exhaust. More fuel in the tank means a little more exhaust. That does not automatically mean the engine is failing. What the Evidence Actually Supports Creatine monohydrate is one of the most studied dietary supplements we have — hundreds of trials over three decades. The International Society of Sports Nutrition has called it the most effective ergogenic nutritional supplement currently available for increasing high-intensity exercise capacity and lean mass during training. What holds up Strength and lean mass when you train. Combined with resistance training, creatine reliably improves strength and adds lean mass — often around 1 kg of additional lean mass on average, with larger gains in some studies — over 8–12 weeks in study settings. It does not replace training. It helps you do a little more work in the sessions you already do. Aging muscle (sarcopenia). We lose muscle with age. That loss is not cosmetic. It affects balance, blood sugar handling, recovery from illness, and independence. Creatine plus protein plus actual strength work is one of the more practical stacks we have for older adults. People who eat little or no animal protein. Vegetarians and vegans start with lower muscle creatine stores. They frequently see substantial increases in tissue creatine after supplementation, although evidence that their performance response is always greater than omnivores is mixed. In practice, many notice a real difference. Brain energy under stress. The brain uses creatine too. The performance data is strongest for muscle. The cognitive data is newer and smaller, but directionally interesting: a 2024 meta-analysis found modest benefits for memory and some processing measures, particularly under sleep deprivation or metabolic stress. Preliminary adjunctive research in depression exists, but the clinical benefit remains very uncertain. I treat the cognitive angle as promising, not settled. Postmenopausal women. A 2026 meta-analysis found a small increase in lean mass (roughly 0.37 kg) and improved leg-press strength when creatine — especially at doses of 5 grams per day or more — accompanied resistance training. Bone-density benefit was not demonstrated overall, but the muscle and strength conversation overlaps meaningfully with the bone conversation in this population. Evidence is growing, not finished. What does not hold up Creatine is not a steroid. Creatine is not a fat-gain drug. Early scale weight is mostly intramuscular water. Fancy forms (ethyl ester, "buffered," many patented variants) have not beaten plain creatine monohydrate in head-to-head work. Some — creatine ethyl ester in particular — convert to creatinine faster and actually perform worse. Pay for purity and third-party testing, not for a new molecule name. Does Creatine Damage the Kidneys? In healthy people, at usual doses, the best available evidence says no. What creatine does do is raise the lab number we use as a kidney proxy. Creatine can modestly increase serum creatinine because more creatine is available for conversion to creatinine. Recent meta-analyses — including two published in 2026 — found an average serum creatinine increase of about 0.13–0.14 mg/dL. Creatinine-based eGFR may therefore appear lower even when true kidney filtration has not changed. Crucially, when researchers measured filtration directly using creatinine-independent methods (such as Cr-EDTA clearance), they found no change. That strongly suggests a measurement artifact, not nephron injury. Side-effect rates in pooled trial data look similar to placebo; the most common complaints are gastrointestinal discomfort if the dose is dumped in all at once. One nuance worth noting: long-term randomized data beyond approximately one year are much thinner than the short- and medium-term evidence. So I will not say renal safety has been proved indefinitely in every population. What I will say is that the current evidence, across a large number of studies, has not shown a signal of kidney damage in healthy adults using recommended doses. The caveat is real and I do not wave it away: Known chronic kidney disease eGFR already reduced Nephrotoxic medications Unexplained rising creatinine before anyone started creatine Pregnancy and lactation (not enough safety data) Those are "talk to your physician first" situations, not internet-protocol situations. If you are already on creatine and a routine panel looks worse, tell the person reading the labs. Ask whether cystatin C — a kidney marker that is not generated from creatine metabolism and is less dependent on muscle mass — would clarify the picture. Combining creatinine and cystatin C can sometimes give a more informative estimate than relying on creatinine alone. Temporarily stopping creatine and repeating testing after an appropriate interval can also sometimes clarify the picture. How I Think About Dosing in Practice There are two honest ways to saturate muscle stores. Daily low dose (what most people should do): 3–5 grams of creatine monohydrate every day. Saturation takes three to four weeks. Fewer GI issues. No drama. Optional loading: About 20 grams a day, split into 4 doses of roughly 5 grams each, for 5–7 days, then 3–5 grams daily. Faster saturation. More water retention and more GI complaints. Not required. I generally skip loading unless someone has a time-sensitive training block and tolerates split doses. Consistency beats cleverness. Practical notes that matter more than timing debates Take it with food if your stomach is sensitive. Maintain normal hydration. Creatine can increase intracellular water, especially early in supplementation, but controlled studies do not show that it causes dehydration. Powder is cheaper and fine. Capsules are convenience, not magic. Look for creatine monohydrate, ideally Creapure or another batch that is third-party tested (NSF, Informed Sport, USP). The risk in this category is usually a dirty product, not the molecule. You do not need to "cycle" it if you are healthy and the dose is ordinary. Who Is a Reasonable Candidate — and Who Is Not Reasonable to discuss: People who lift or do repeated high-intensity work Adults over 50 trying to keep muscle Vegetarians and vegans Patients whose fatigue picture includes low training capacity and who already have a training plan Some women in peri- and postmenopause, where muscle and bone conversations overlap Pause and get medical input first: Established kidney disease Unexplained abnormal creatinine or eGFR Heart failure with tight fluid management Adolescents should not self-experiment; use should occur with appropriate parental and professional supervision. The ISSN considers supervised use acceptable in appropriately trained young athletes, but that is different from a teenager ordering it online. Pregnancy and breastfeeding — human supplementation safety data remain insufficient to recommend routine use Creatine is not a treatment for fibromyalgia, MCAS, autoimmune disease, or cancer. In my practice those conditions have their own frameworks. If someone in that group also wants to protect muscle while they train, we talk about labs, hydration, and the creatinine-lab artifact before they start — not after a panicked portal message. How This Fits a Functional Medicine Visit A supplement is never the first question I ask. The first questions are still the boring ones that change outcomes: protein intake, resistance training two or three days a week, sleep, hydration, and whether the person can actually recover from the work they are doing. If those pieces are in place, creatine monohydrate is one of the few supplements with a risk-benefit ratio I am comfortable discussing in clinic. If those pieces are missing, creatine will not rescue the plan. If you are a patient of Yoon Hang Kim MD and you start creatine, put it on your supplement list and tell me before the next lab draw. That single sentence prevents a lot of unnecessary alarm. Frequently Asked Questions About Creatine Is creatinine a supplement? No. Creatinine is a waste product. The supplement is creatine. Will creatine make my creatinine high? It can raise the number modestly. That is not the same as kidney failure. Context and, when needed, a second marker like cystatin C matter. What form of creatine should I buy? Creatine monohydrate. Micronized dissolves more easily. Everything else needs a better reason than marketing. Do I need a loading phase? No. Helpful if you want saturation in a week. Unnecessary if you can wait a month. Can I take creatine with LDN or other medications? No specific interaction between creatine and low-dose naltrexone has been established in the published literature, although formal interaction data are limited. The practical issue is the creatinine lab, not a drug-drug clash. Medication lists still belong in the conversation with your prescriber. Does creatine cause hair loss? An older small study raised concern about a DHT shift in a group of rugby players. However, a 2025 randomized trial measured DHT and actual hair-follicle and hair-density outcomes after 12 weeks of 5 grams per day of creatine and found no significant differences from placebo. Current evidence does not support creatine causing hair loss. Summary What creatine is: A naturally occurring compound stored primarily in skeletal muscle that helps regenerate ATP during short, high-intensity efforts. Your body makes about 1 gram per day; diet adds 1–2 grams; supplementation can raise muscle stores by 20–40%. What the evidence supports: Creatine monohydrate, at 3–5 grams daily, reliably improves strength and lean mass when combined with resistance training. Benefits extend to older adults fighting sarcopenia, vegetarians and vegans with lower baseline stores, and postmenopausal women. Cognitive benefits under metabolic stress are promising but not yet settled. What it does to your labs: Creatine raises serum creatinine by roughly 0.13–0.14 mg/dL on average, which can make eGFR look lower. Two 2026 meta-analyses confirmed this is a measurement artifact — directly measured kidney filtration does not change. This is not kidney damage. It is more exhaust from a fuller tank. What it does not do: It is not a steroid. It does not cause dehydration. It does not cause hair loss (a 2025 randomized trial found no effect on DHT or hair density). Fancy branded forms have not outperformed plain creatine monohydrate. Who should pause: Anyone with established kidney disease, unexplained abnormal creatinine, heart failure with tight fluid management, unsupervised adolescents, or women who are pregnant or breastfeeding should get medical guidance before starting. The bottom line: Creatine monohydrate is one of the best-supported, lowest-risk, and least expensive supplements available for healthy adults who train. If your creatinine rose after you started it, do not panic and do not ignore it. Bring the bottle, the dose, and the timeline to the clinician who ordered the labs. That conversation is the whole point. The Honest Bottom Line Creatine monohydrate is not a miracle, and it is not a menace. For healthy adults who train, eat enough protein, and understand what their labs mean, it is one of the better-supported, inexpensive tools we have for muscle and high-intensity work. For people with real kidney disease, it is a medical decision, not a cart-checkout decision. If your creatinine rose after you started creatine, do not panic and do not ignore it. Bring the bottle, the dose, and the timeline to the clinician who ordered the labs. If you want help sorting whether creatine belongs in your plan — next to the rest of your history, medications, and labs — that is the kind of conversation we have at Yoon Hang Kim MD. ——— Yoon Hang "John" Kim, MD, MPH, FAAMA, is a board-certified preventive medicine physician specializing in integrative and functional medicine. He is an IFM Scholar, a graduate of the University of Arizona Integrative Medicine Fellowship under Dr. Andrew Weil, and provides telemedicine care through Yoon Hang Kim MD to patients in Iowa, Illinois, Missouri, Georgia, Florida, and Texas. This article is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting or changing any supplement or treatment.

By Yoon Hang Kim, MD, MPH Board-Certified in Preventive Medicine | Integrative & Functional Medicine Physician Low dose naltrexone (LDN) is often discussed as though there is one standard dose, one predictable response, and one straightforward way to use it. In clinical practice, it is rarely that simple. People differ dramatically in sensitivity, diagnosis, immune function, nervous system reactivity, medication tolerance, and response to dose changes. This becomes especially important in patients with mast cell activation syndrome (MCAS), multiple chemical sensitivity, chronic pain, neuropathy, autoimmune disease, and complex chronic illness. During a recent LDN Support Group live session, I answered questions about some of the most common challenges people encounter with LDN. What follows are the key teaching points from that conversation. LDN and Neuropathic Pain One question involved using LDN for an "overactive nerve" that flares easily. Without knowing the underlying diagnosis, it is difficult to say exactly what is being treated. However, when we are talking about neuropathic pain, LDN may be working through mechanisms beyond simply blocking opioid receptors and increasing endogenous endorphins. One proposed mechanism involves Toll-like receptor 4 (TLR4), which is associated with glial-cell activation and neuroinflammation. When TLR4 is activated on microglia — the most prevalent immune cells of the nervous system — it can trigger a cascade of proinflammatory cytokines including interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α). LDN appears to act as a TLR4 antagonist, competitively binding to the receptor and blocking downstream inflammatory signaling (Parkitny & Younger, 2017; Toljan & Vrooman, 2018). This mechanism is particularly interesting when we think about neuropathic pain. I experienced this personally after surgery. I developed significant nerve pain and was prescribed opioids and gabapentin. The gabapentin affected me so strongly that I could barely walk safely and needed two canes. I ultimately used naltrexone along with non-opioid pain strategies, and it made a major difference for me. One important point is that dosing for neuropathic pain may not necessarily be identical to dosing used for autoimmune or other conditions. The diagnosis matters. Related reading: LDN, Emotional Distress, Neuropathy, Chronic Fatigue Syndrome, and Mitochondrial Support What If LDN Causes Headache or Nausea? Another person described starting at 0.25 mg, increasing to 0.5 mg after two weeks, and eventually reaching 0.75 mg. They subsequently developed persistent headaches and nausea. When symptoms appear after increasing LDN, I generally do not recommend simply pushing through them. My usual clinical approach is to back off. That may mean stopping the medication temporarily, allowing symptoms to settle, and — if LDN is restarted — returning at a much lower dose and titrating much more slowly. I sometimes describe this pattern as being consistent with an inadequate endorphin response or "endorphin deficiency" relative to the degree of opioid receptor blockade. Whatever terminology we use, the practical message is the same: if the dose is making you significantly worse, more is not necessarily better. Related reading: The Endorphin Depletion Hypothesis in CFS/ME LDN, Vivid Dreams, and Insomnia Sleep disruption is one of the more commonly reported challenges with LDN. People may experience vivid dreams, difficulty falling asleep, or severe insomnia. When someone tells me they are taking a "low dose," however, I usually ask: What dose? The phrase "low dose" is not precise enough. For one person, 4.5 mg may be considered low dose. For another person, 0.25 mg may be far too much. A highly sensitive patient may need to begin in the microgram range. Rather than saying, "I'm taking a low dose," tell your clinician: "I'm taking 0.5 mg." That makes the conversation much more useful. When insomnia becomes severe after starting or increasing LDN, I consider the possibility that the dose is simply too high for that individual. Stopping and restarting much lower may be more productive than continuing to increase. Related reading: LDN in Functional Medicine: A Practical Guide Can Symptoms Get Worse After Increasing LDN? Yes. A person may improve at one dose and then worsen after increasing it. That may look paradoxical, but biological systems do not always follow a simple linear dose-response curve. More medication does not automatically mean more benefit. This is why I believe patients should participate actively in determining their LDN dosing strategy. You are the person experiencing the medication every day. Pay attention. Keep notes. Watch what happens to your sleep, pain, energy, gastrointestinal symptoms, mood, cognition, and other symptoms as the dose changes. Individual observation can be extremely valuable. Blood in the Stool Is Not an LDN Question One participant described a 19-year-old with MCAS who was taking LDN. Energy had improved, but severe insomnia persisted. The person also had chronic diarrhea and blood in the stool. At that point, the most important issue is not adjusting LDN. Blood in the stool requires appropriate medical evaluation. Inflammatory bowel disease is one possibility, and LDN has historically been studied in inflammatory bowel disease, including pediatric populations (Smith et al., 2013). But LDN should not become a substitute for establishing the diagnosis. If there is persistent diarrhea, bleeding, or another concerning symptom, seek appropriate medical evaluation. Treating presumed disease without first evaluating serious possibilities can be dangerous. Can LDN Help Autoimmune Disease? Another question came from someone with multiple autoimmune or inflammatory conditions, including Hashimoto's thyroiditis, lichen-related disease, and psoriasis. I have seen patients with autoimmune disorders benefit from LDN. A 2019 Norwegian registry study found that persistent LDN users with rheumatoid arthritis showed a 13% relative reduction in dispensing of all rheumatic medications and a 23% reduction in analgesic use (Raknes & Småbrekke, 2019). But I would strongly caution against thinking, "LDN must fix this." Responses are highly individual. LDN may help modulate inflammation or symptoms, but it should not automatically be viewed as a cure or as an emergency medication designed to extinguish every inflammatory process. Sometimes conventional medicine is exactly what is needed to "put out the fire." LDN may then serve as one component of a larger strategy. MCAS Patients May Need Extremely Small Doses One person with MCAS told their physician they were highly medication-sensitive and wanted to start with a microdose. They were started at 1 mg. For some patients with MCAS, 1 mg can be an enormous starting dose. In my own practice, particularly sensitive MCAS patients may begin around the microgram range. One milligram equals 1,000 micrograms. That difference matters. Highly sensitive patients should not necessarily be treated using the same titration schedule as the average patient. MCAS changes the equation. Related reading: MCAS: A New Epidemic in Plain Sight MCAS Diagnosis Requires Flexible Thinking MCAS can also be challenging because laboratory testing is imperfect. There are diagnostic criteria and laboratory protocols, but no single test perfectly identifies every patient with mast cell activation. Timing also matters. Histamine and related mediators may be transient, and some testing is most informative when performed during active symptoms. Twenty-four-hour metabolite testing may sometimes help, but even that is not perfect. Because we do not have a single test with perfect sensitivity, clinical reasoning remains important. We should consider symptoms, history, response patterns, laboratory information, and alternative diagnoses together. Rigid thinking can cause clinicians to miss patients whose presentation does not fit neatly into one laboratory box. Related reading: The COMT Gene and Mast Cell Activation Syndrome: Mechanistic Links, Clinical Implications, and the Limits of Current Evidence LDN Is Usually Not Emergency Treatment for MCAS One of the biggest misconceptions I see is the expectation that long-term immune-modulating therapy should behave like emergency treatment. People frequently come to me when they are desperate. Understandably, they want something that works immediately. Sometimes a patient does experience rapid improvement. But for many patients with MCAS, treatment requires weeks or months. The strategy may involve introducing one intervention, evaluating tolerance, titrating carefully, and then deciding whether another intervention should be added. That process cannot always be rushed. Even medications such as omalizumab (Xolair) may require months before clinicians can properly judge the response. Immune modulation takes time. Related reading: Lactobacillus rhamnosus GG (LGG) in Mast Cell Activation Syndrome When You Have Multiple Diagnoses, Fight One Dragon at a Time Another participant had a combination of chronic pain, autoimmune disease, fibromyalgia, occipital neuralgia, Hashimoto's disease, anxiety, and possibly polymyalgia rheumatica. These are not simple cases. When someone has many overlapping diagnoses, I often use the analogy of being surrounded by dragons. LDN is one weapon. Trying to fight every dragon simultaneously with the same weapon usually creates confusion. Instead, decide which dragon matters most. What is the primary problem? What condition is driving the greatest disability? What needs urgent conventional treatment? What problem can reasonably be addressed next? In complex patients, I often prefer to address one major target at a time rather than changing five medications and ten supplements simultaneously. Otherwise, when something improves — or worsens — you may have no idea why. If You Are Feeling Better, What Should You Stop First? Someone asked what to reduce when they are doing well but taking LDN, ketotifen, exogenous ketones, and a large number of supplements. This is another situation where individualized medical guidance helps. In my practice, I generally do not start by removing necessary prescription medication. I am more likely to first examine the supplement list. Does every supplement still have a purpose? Was it originally prescribed for a problem that has now resolved? Are multiple products duplicating ingredients? Can the regimen be simplified? Exogenous ketones are another area worth examining. Your body can make ketones through nutritional ketosis. Exogenous ketones may have specific uses, but they are not automatically necessary simply because someone benefits from ketosis. Simplification should be thoughtful, deliberate, and preferably performed one change at a time. Sublingual and Topical LDN Questions also come up about sublingual and topical LDN. Based on discussions I have had with compounding pharmacists, these routes may sometimes produce inconsistent results. One potential issue is the carrier and how effectively the medication reaches systemic circulation. Transdermal delivery in particular depends heavily on formulation. Although I may think experimentally about different carriers, I am not a compounding pharmacist, and formulation decisions should ultimately be made with someone who understands pharmaceutical compounding. Route of administration matters just as much as the number printed on the bottle. "It Was Working Until I Increased the Dose" Another participant had done very well at 3.5 mg but developed worsening pain after increasing to 4 mg. They then reduced to 3 mg after a 24-hour break. This is a common lesson with LDN: if 3.5 mg works, you do not necessarily need 4 mg. There is no prize for reaching the highest dose. The goal is to identify the dose that produces the best overall response. For some people, a 24-hour break may also be too short after developing a significant adverse reaction. In particularly sensitive patients, allowing more time for the system to settle may be reasonable before deciding what to do next. What Does "Microdose" Actually Mean? Terminology around LDN has become confusing. People sometimes describe 1 or 2 mg as a "microdose." Technically, however, a microgram dose is very different from a milligram dose. For example: 1 mg = 1,000 micrograms. 2 mg = 2,000 micrograms. When discussing LDN, I encourage people to stop relying on vague terms such as "low dose," "very low dose," "ultra-low dose," or "microdose." Instead, simply state the actual dose. The number provides much more useful clinical information. The published literature distinguishes these ranges more precisely. Toljan and Vrooman (2018) define LDN as 1–5 mg/day, very low-dose naltrexone (VLDN) as 1 µg–1 mg, and ultra-low-dose naltrexone (ULDN) as less than 1 µg/day. These distinctions carry different pharmacodynamic implications. Chronic Fatigue Requires a Differential Diagnosis We also discussed testing for chronic fatigue. There is considerable interest in newer biomarkers and specialized tests. Those tests can be useful. But chronic fatigue should still trigger a broader medical evaluation. The differential diagnosis may include sleep disorders, endocrine abnormalities, nutritional deficiencies, infections, autoimmune disease, hormonal problems, and other medical conditions. Performing one specialized test while ignoring the major differential diagnoses is not comprehensive medicine. A better approach is to systematically evaluate the common and important possibilities while integrating newer testing when appropriate. Related reading: The Endorphin Depletion Hypothesis in CFS/ME Rotate Sleep Tools Rather Than Depending on One Thing Forever A final question involved supplements for sleep and mood. One general strategy I use is to avoid relying on the same sleep intervention every night whenever possible. If one intervention works, perhaps use it selectively. Find another strategy that also works. And another. The goal is to develop a toolbox. For example, someone might rotate among several appropriate strategies rather than repeatedly depending on one intervention until its effectiveness diminishes. Sleep is complex, and sometimes having several tools is more sustainable than looking for one perfect solution. The Bigger Lesson: LDN Is Highly Individualized LDN can be remarkably useful. I have seen it help with neuropathic pain, autoimmune conditions, inflammatory disorders, and complex chronic illness. I have also seen people develop insomnia, nausea, headaches, worsening symptoms, or paradoxical reactions when the dose is wrong for them. The lesson is not that LDN is good or bad. The lesson is that LDN is individualized. The right question is often not, "What is the correct LDN dose?" It is: "What is the correct LDN dose for this particular person, for this particular condition, at this particular point in time?" Start thoughtfully. Pay attention to your response. Do not assume that increasing the dose will increase the benefit. And when dealing with MCAS or highly medication-sensitive patients, remember that sometimes the difference between success and failure is simply starting much, much lower. References Parkitny L, Younger J. Reduced pro-inflammatory cytokines after eight weeks of low-dose naltrexone for fibromyalgia. Biomedicines. 2017;5(2):16. doi:10.3390/biomedicines5020016 Toljan K, Vrooman B. Low-dose naltrexone (LDN) — review of therapeutic utilization. Medical Sciences. 2018;6(4):82. doi:10.3390/medsci6040082 Raknes G, Småbrekke L. Low dose naltrexone: effects on medication in rheumatoid and seropositive arthritis. A nationwide register-based controlled quasi-experimental before-after study. PLoS One. 2019;14(2):e0212460. doi:10.1371/journal.pone.0212460 Smith JP, Stock H, Bingaman S, Mauger D, Rogosnitzky M, Zagon IS. Low-dose naltrexone therapy improves active Crohn's disease. Am J Gastroenterol. 2007;102(4):820-828. doi:10.1111/j.1572-0241.2007.01045.x Smith JP, Bingaman SI, Ruber F, et al. Therapy with the opioid antagonist naltrexone promotes mucosal healing in active Crohn's disease: a randomized placebo-controlled trial. Dig Dis Sci. 2011;56(7):2088-2097. doi:10.1007/s10620-011-1653-7 Pogue J, Johnson D, Burch A. A utilization review of patients that respond to low-dose naltrexone (LDN) for chronic pain. J Pain Res. 2023;16:1993-1998. doi:10.2147/JPR.S389957 McKenzie-Brown AM, Boorman DW, Ibanez KR, et al. Real world effectiveness and tolerability of low dose naltrexone to treat chronic pain. J Pain Res. 2024;17:1273-1284. doi:10.2147/JPR.S451183 Younger J, Noor N, McCue R, Mackey S. Low-dose naltrexone for the treatment of fibromyalgia: findings of a small, randomized, double-blind, placebo-controlled, counterbalanced, crossover trial assessing daily pain levels. Arthritis Rheum. 2013;65(2):529-538. doi:10.1002/art.37734 More from IFMSynergy LDN in Functional Medicine: A Practical Guide LDN, Emotional Distress, Neuropathy, Chronic Fatigue Syndrome, and Mitochondrial Support The Endorphin Depletion Hypothesis in CFS/ME MCAS: A New Epidemic in Plain Sight The COMT Gene and MCAS: Mechanistic Links and Clinical Implications Lactobacillus rhamnosus GG (LGG) in MCAS Medical Disclaimer: This article is for educational and informational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any disease. Always consult a qualified healthcare professional before starting any new treatment, supplement, or medication. Individual responses to therapies vary, and the information presented here should not replace the clinical judgment of your physician. Yoon Hang Kim, MD, MPH LDN Support Group | www.ldnsupportgroup.org IFMSynergy | www.ifmsynergy.com

By Yoon Hang "John" Kim, MD, MPH I can't tell you how many patients walk into my office already taking melatonin — sometimes way more than they need — and still not sleeping. They're frustrated. They did the "natural" thing. It didn't work. Now what? That's usually when I bring up saffron, and I get the look. The cooking spice? Sort of. We're not talking about pinching threads into your rice. We're talking about a concentrated, standardized extract that's been put through legitimate clinical trials. And honestly, the data surprised me when I first dug into it. What does the research actually show? Multiple randomized, controlled trials have studied saffron extract for sleep — real studies with placebo groups and measurable outcomes. The results have been consistent: participants who took standardized saffron extract before bed reported meaningful improvements in sleep quality, fell asleep faster, and slept longer. Several studies also showed that saffron increased the body's own evening melatonin production — without taking melatonin from the outside.[1,2,3] Most people notice a shift within three to four weeks of consistent use. This isn't something that knocks you out on night one. It builds. For specific dosing guidance and a deeper dive into the clinical evidence, visit my academic blog at www.ifmsynergy.com. A few things worth knowing Get the right product. The extract studied most is called Affron®. It's standardized to the active compounds — crocins and safranal. The saffron in your spice cabinet won't cut it. Be patient. Four weeks minimum. Some trials ran eight weeks. This is a slow burn, not a sedative. Talk to your doctor. Saffron can amplify sedative medications, and it should be avoided during pregnancy. At the doses used in clinical research, it has an excellent safety profile — but it's always worth a conversation with your provider.[10] Two supplements, two completely different jobs People lump melatonin and saffron together as "natural sleep aids," but they're doing fundamentally different things in your body. Melatonin is a hormone. When you swallow it, you're adding it from the outside. It talks to the receptors in your brain that set your internal clock, which makes it genuinely useful when the timing of your sleep is the problem — jet lag, night shifts, a body clock that runs two hours late. Saffron works on a different level entirely. It supports the brain pathways that calm you down — the same ones tangled up in stress and anxiety. And here's the part that really caught my attention as a clinician: saffron doesn't replace your melatonin. It nudges your body into making more of its own.[2] That matters. There's growing concern that taking melatonin from the outside — especially at the high doses people tend to use — can dial down your body's natural production over time. Saffron seems to push things in the other direction. How do they compare in the research? When you put the trial outcomes next to each other, the difference is hard to ignore — at least for the kind of sleep trouble most people deal with. In studies of people with chronic, stress-related insomnia, saffron consistently produced larger improvements in how fast people fell asleep, how long they stayed asleep, and how efficient their sleep was overall. Melatonin, by contrast, showed more modest results for primary insomnia — but strong results for circadian-related issues like jet lag and shift work.[1,2,7] For the lying-awake-at-2am-with-your-brain-on-fire kind of insomnia, saffron has the stronger evidence. But if your issue is that your body doesn't know what time zone it's in, melatonin is still the right call. For a detailed comparison of the clinical outcomes, visit www.ifmsynergy.com. How I think about it in practice My framework is simple. I lean toward saffron when someone's sleep trouble comes packaged with stress, worry, or a mind that won't stop running. That's the majority of my clients. Saffron is safe for longer-term use, supports the body's own chemistry, and the trial data backs it up. I lean toward melatonin when the core issue is timing. Jet lag. Rotating shifts. A teenager whose body clock thinks midnight is 10 PM. Sometimes I use both. They're not competing; they're working on different systems. Where this leaves us Saffron isn't going to fix everything. No supplement will. If your sleep hygiene is a mess, if you haven't been screened for sleep apnea, if you're doom-scrolling until midnight and wondering why you can't fall asleep — we need to address that first. But as one piece of a bigger plan? Standardized saffron extract is one of the better-supported natural options available right now for chronic, stress-driven insomnia. The research is real. The safety margin is wide. And in my experience, clients who try it tend to stick with it — which tells me something. If melatonin hasn't been doing the job, it might be time for a different conversation. Dr. Kim is board-certified in Preventive Medicine and practices integrative & functional medicine. He is the author of MCAS: Epidemic in Plain Sight and LDN Primer, both available on Amazon. He is also the founder of the LDN Support Group. References Lopresti AL, Smith SJ, Metse AP, Drummond PD. Effects of saffron on sleep quality in healthy adults with self-reported poor sleep: a randomized, double-blind, placebo-controlled trial. J Clin Sleep Med. 2020;16(6):937–947. Lopresti AL, Smith SJ, Drummond PD. An investigation into an evening intake of a saffron extract (affron®) on sleep quality, cortisol, and melatonin concentrations in adults with poor sleep: a randomised, double-blind, placebo-controlled, multi-dose study. Sleep Med. 2021;86:7–18. Pachikian BD, Copine S, Suchareau M, Deldicque L. Effects of saffron extract on sleep quality: a randomized double-blind controlled clinical trial. Nutrients. 2021;13(5):1473. Schuster J, Mundhenke C, Nordsieck H, Pouchieu C, Pourtau L, Hahn A. Effect of a saffron extract on sleep quality in adults with moderate insomnia: a decentralized, randomized, double-blind, placebo-controlled trial. Sleep Medicine: X. 2025;10:100147. Lian Y, Yin F, Yang C, et al. Effects of saffron supplementation on improving sleep quality: a meta-analysis of randomized controlled trials. Sleep Med. 2022;92:24–33. Rafiei SKS, Abolghasemi S, Frashidi M, et al. Saffron and sleep quality: a systematic review of randomized controlled trials. Nutr Metab Insights. 2023;16:11786388231160317. Ferracioli-Oda E, Qawasmi A, Bloch MH. Meta-analysis: melatonin for the treatment of primary sleep disorders. PLoS One. 2013;8(5):e63773. Bruni O, Ferini-Strambi L, Giacomoni E, Pellegrino P. Herbal remedies and their possible effect on the GABAergic system and sleep. Nutrients. 2021;13(2):530. Shafiee M, Arekhi S, Omranzadeh A, Sahebkar A. Saffron in the treatment of depression, anxiety and other mental disorders: current evidence and potential mechanisms of action. J Affect Disord. 2018;227:330–337. Mehri S, Razavi BM, Hosseinzadeh H. Safety and toxicity of saffron. In: Koocheki A, Khajeh-Hosseini M, eds. Saffron. Woodhead Publishing; 2020:517–530. Kell G, Rao A, Beccaria G, Clayton P, Inarejos-García AM, Prodanov M. affron® a novel saffron extract (Crocus sativus L.) improves mood in healthy adults over 4 weeks in a double-blind, parallel, randomized, placebo-controlled clinical trial. Complement Ther Med. 2017;33:58–64.

When Eating Feels Like a Minefield: A Story of MCAS, Ketotifen, and Low-Dose Naltrexone By Yoon Hang Kim, MD, MPH Board-Certified in Preventive Medicine | Integrative & Functional Medicine Physician 🎥 Watch the short version: MCAS, Ketotifen & LDN — a client story For people living with mast cell activation syndrome (MCAS), eating can feel like a minefield. A food that was fine last month triggers flushing, hives, gut pain, or brain fog today. Over time, many people respond the only way that feels safe: they eliminate. First the obvious triggers, then the suspicious ones, then anything uncertain — until the "safe list" has shrunk to a handful of foods and mealtimes are ruled by fear rather than nourishment. I want to share a story from my practice about how the right combination — introduced slowly and carefully — made a remarkable difference for one client. And, just as importantly, what that story does and doesn't mean for anyone else navigating MCAS. A Shrinking Plate One of my clients with MCAS had become extremely limited in the foods they could tolerate. This is one of the most distressing places an MCAS journey can lead. Beyond the nutritional concerns, there is a psychological weight to it: every meal becomes a risk calculation, social eating disappears, and the world gets smaller. When someone arrives at this point, my goal is never to find a miracle. It is to find traction — some stabilization of the mast cell system that gives the body room to expand again. The Combination: Ketotifen + LDN For this client, we carefully introduced two medications together: Compounded ketotifen. Ketotifen is an older antihistamine with a second, less widely known property: it acts as a mast cell stabilizer, helping to reduce the release of histamine and other inflammatory mediators at the source rather than just blocking their effects downstream (Grant et al., 1990). In the United States it is not commercially available as an oral tablet, so it is typically prepared by a compounding pharmacy, which also allows very gradual dose titration — something MCAS clients often need. Low-dose naltrexone (LDN). At low doses, naltrexone appears to act quite differently than at standard doses, modulating glial cells and inflammatory signaling in ways that have made it a subject of growing interest for chronic inflammatory and pain conditions (Younger, Parkitny & McLain, 2014). In my practice, LDN has been a foundational tool for many clients with MCAS, autoimmunity, and chronic pain — always started low and adjusted patiently. The result for this client? Over time, they were able to tolerate a much wider variety of foods. Meals stopped being a minefield and started being meals again. The Important Part: There Is No Universal Protocol Here is what I most want readers to take from this story — and it is not "ketotifen plus LDN treats MCAS." MCAS treatment is highly individualized. The condition itself is heterogeneous: mast cells can misbehave in different ways in different people, and triggers, mediators, and comorbidities vary enormously from one person to the next (Molderings et al., 2011). There is no single medication, dose, or protocol that works for everyone. What produced a breakthrough for this client may do little for another — and something entirely different may be that person's key. In my experience, progress in MCAS usually comes from a few unglamorous principles: Go slowly. Start one change at a time, at low doses, so the body — and the clinician — can tell what is actually happening. Adjust carefully. Titration in MCAS is a craft. Sensitive systems often need smaller steps than standard dosing guides suggest. Let the body vote. Symptom response, not protocol adherence, guides the next step. Expand, don't just restrict. The goal of stabilization is to widen the safe list again — restriction is a temporary shelter, not a destination. Why This Is Personal After years of seeing MCAS both personally and professionally, I've learned that individualized care matters enormously. Behind every shrinking food list is a person who has usually been dismissed, misdiagnosed, or told their symptoms don't fit a pattern. They fit a pattern — just not a common one. Taking that pattern seriously, and working through it one careful step at a time, is where recovery begins. References Grant SM, Goa KL, Fitton A, Sorkin EM. Ketotifen: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in asthma and allergic disorders. Drugs. 1990;40(3):412–448. Younger J, Parkitny L, McLain D. The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain. Clinical Rheumatology. 2014;33(4):451–459. Molderings GJ, Brettner S, Homann J, Afrin LB. Mast cell activation disease: a concise practical guide for diagnostic workup and therapeutic options. Journal of Hematology & Oncology. 2011;4:10. Important: This article is for educational purposes only and does not constitute medical advice. MCAS is a complex condition, and treatment decisions — including the use of ketotifen or low-dose naltrexone — should always be made in partnership with a qualified healthcare professional who knows your individual situation. About Dr. Kim Dr. Yoon Hang "John" Kim is a board-certified physician with over 20 years of experience in integrative medicine. He completed his fellowship training under Dr. Andrew Weil at the University of Arizona and holds board certifications in Preventive Medicine as well as certifications in medical acupuncture and integrative & holistic medicine. He specializes in low-dose naltrexone (LDN) therapy, autoimmune conditions, chronic pain, integrative oncology, fibromyalgia, chronic fatigue syndrome, MCAS, and mold toxicity. Dr. Kim is the author of three books and more than 20 peer-reviewed articles. Professional: www.yoonhangkim.com | Clinical: www.directintegrativecare.com Yoon Hang Kim MD | www.directintegrativecare.com | 📞 (210) 981-6106 Follow for more on MCAS, low-dose naltrexone, functional medicine, and integrative medicine. #MCAS #MastCellActivationSyndrome #LowDoseNaltrexone #LDN #Ketotifen #FunctionalMedicine #IntegrativeMedicine #ChronicIllness #MastCells

Functional Medicine in San Antonio: A Root-Cause Approach with Yoon Hang Kim, MD, MPH Board-Certified in Preventive Medicine | Integrative & Functional Medicine Physician If you've spent years cycling through specialists, tests, and prescriptions — and you still don't feel well — the problem may not be you. It may be the model of care. Conventional medicine excels at acute crises, but chronic, complex illness often demands a different question: not "What is the diagnosis?" but "Why is this happening in the first place?" That question is the foundation of functional medicine, and it's the question Yoon Hang Kim, MD, MPH has spent more than two decades answering for clients with conditions that don't fit neatly into a fifteen-minute visit. Why Root Cause Matters Symptoms are signals, not the disease itself. Fatigue, brain fog, chronic pain, digestive distress, and recurring inflammation are downstream effects of underlying imbalances — immune dysregulation, hormonal disruption, gut dysfunction, environmental exposures, or chronic stress physiology. Suppressing the signal without addressing the source is why so many people feel stuck. Functional medicine works differently. It examines how your body's systems interact, then builds a plan around your biology, history, and life — not a protocol designed for the average patient who doesn't actually exist. Who This Approach Serves Best Dr. Kim's practice focuses on the conditions where root-cause medicine offers the most leverage: Autoimmune conditions — including low-dose naltrexone (LDN) therapy, an area where Dr. Kim has published and lectured extensively Mast Cell Activation Syndrome (MCAS) and complex multi-system illness Fibromyalgia and chronic fatigue syndrome Chronic pain — integrating medical acupuncture (UCLA certification) with modern pharmacology Mold toxicity and environmental illness Integrative oncology support — care alongside, never instead of, your oncology team What Working with Dr. Kim Looks Like Time, first. The practice is deliberately capped at a small number of active clients. That structural choice means consultations are unhurried, follow-up is real, and your case gets the sustained attention complex illness requires. This isn't a marketing claim — it's how the practice is built. A thorough investigation. Your first visit involves a detailed health history and, where appropriate, advanced testing to identify hidden drivers: inflammation markers, hormonal patterns, gut dysfunction, or nutrient deficiencies. A personalized, evidence-informed plan. Nutrition, targeted supplementation, stress physiology work, and conventional treatments when they're the right tool. Integrative medicine is not alternative medicine — it's using the full toolkit, judiciously. A partnership. You are the central actor in your own recovery. Dr. Kim's role is to bring twenty-plus years of clinical judgment to your side of the table — and to adjust the plan as your body responds. Why Membership-Based Care Changes Everything Most of what frustrates people about healthcare — rushed visits, surprise bills, months-long waits, playing phone tag through a portal — isn't caused by bad doctors. It's caused by the insurance-driven volume model, where a physician must see 25–30 patients a day to keep the lights on. Membership-based direct care removes that constraint entirely. Here's what that means for you in practice: Time that matches the complexity of your case. With the practice capped at 99 active clients — compared to the 2,000–2,500 a typical insurance-based practice carries — visits are as long as your situation requires. Complex illness cannot be untangled in twelve minutes. Direct access to your physician. Questions between visits go to Dr. Kim, not a triage queue. When you're adjusting an LDN dose or managing an MCAS flare, that responsiveness isn't a luxury — it's clinically meaningful. Complete price transparency. A flat monthly membership and a published fee schedule. No surprise bills, no coding games, no wondering what a visit will cost. No insurance middleman in clinical decisions. Treatment plans are built on what your case needs — not on what a payer will authorize. That independence is precisely what makes genuine root-cause work possible. Continuity and telemedicine convenience. Care continues wherever you are in Texas, with licensure across six states for clients who travel or relocate. Your physician knows your full story because he's the one who's been following it. For San Antonio clients managing chronic conditions, this model often costs less than the out-of-pocket total of copays, deductibles, and lost time in a conventional system — while delivering a fundamentally different level of attention. Experience You Can Verify Credentials matter when you're trusting someone with a complex case. Dr. Kim completed fellowship training in integrative medicine at the University of Arizona under Dr. Andrew Weil, is board-certified in Preventive Medicine and in Integrative & Holistic Medicine, and has held leadership roles including Medical Director of Integrative Oncology at Miami Cancer Institute and Enterprise Medical Director at Optum. He founded and ran Georgia Integrative Medicine for a decade, has authored three books and more than twenty peer-reviewed articles, and now serves clients in Texas — including the San Antonio area — through www.directintegrativecare.com. Taking the First Step Chronic illness rewards preparation and boldness in equal measure. If you're ready to stop managing symptoms and start investigating causes: Review the membership tiers and published fee schedule at www.directintegrativecare.com — everything is transparent before you commit Schedule an initial consultation and bring your full story — prior records, failed treatments, and all Expect a genuine investigation, not a quick fix — and a physician who will tell you honestly what integrative medicine can and cannot do for your situation Because membership is capped at 99 active clients, enrollment depends on current availability. If a spot is open when you're ready, that timing works in your favor. Your health story isn't finished. Sometimes it just needs a better editor. About Dr. Kim Dr. Yoon Hang "John" Kim is a board-certified physician with over 20 years of experience in integrative and preventive medicine. He completed his fellowship at the University of Arizona under Dr. Andrew Weil and holds certifications in preventive medicine, medical acupuncture, and integrative & holistic medicine. Dr. Kim specializes in low-dose naltrexone (LDN) therapy, autoimmune conditions, chronic pain, integrative oncology, fibromyalgia, chronic fatigue syndrome, MCAS, and mold toxicity. He is the author of three books and more than 20 peer-reviewed articles. Professional: www.yoonhangkim.com | Clinical: www.directintegrativecare.com

LDN Q&A: Your Questions Answered A Supportive Guide for the LDN Support Group Download your free LDN Primer Booklet from www.LDNSupportGroup.org January 18 2026 Important Disclaimer This guide shares information based on published research and community experiences. It is not medical advice. LDN is a prescription medication that should only be used under the supervision of a qualified healthcare provider. Always consult your doctor before starting, adjusting, or stopping any medication. Part 1: Quick FAQ These are the most common questions we see in our community. For deeper explanations, see the comprehensive guide in Part 2. Q1: Should I take LDN in the morning or at night? There's no universal "right" answer. Nighttime is traditionally recommended, but if you experience insomnia, morning dosing may work better for you. Some people feel drowsy taking it in the morning initially, but this often improves. Try what feels right and give any change at least 1-2 weeks. Q2: I'm having terrible insomnia on LDN. What should I do? Insomnia is one of the most common side effects, especially at night. Options include: switching to morning dosing, reducing your dose, or if you just started, giving it 1-2 weeks to see if it improves. If insomnia persists despite these adjustments, discuss with your prescriber. Q3: Should I push through side effects or reduce my dose? It depends on severity. Mild effects (slight sleep changes, vivid dreams) often resolve in 1-2 weeks. Moderate to severe effects (significant insomnia, bad headaches, vertigo, irritability) are signals to reduce your dose. If symptoms are getting worse rather than better, back off. Q4: I tolerated LDN fine at first, but now I'm getting worse the longer I take it. Why? This pattern happens to some people. LDN's effects can be cumulative, and what your body tolerated initially may become too much over time. Your underlying condition may also have changed. If you've tried reducing doses and breaks without success, discuss with your provider whether to stop. Q5: How slowly should I increase my dose? Standard protocols suggest reaching 4.5 mg in 2-4 weeks, but this is too fast for many people. If you're sensitive or severely ill, consider 2-4 week intervals between increases—or even longer. Some very sensitive patients need months between dose changes. Patience is key. Q6: What's the lowest dose I can try? Clinical protocols recognize ultra-low doses in the microgram range (1-2 mcg), very-low doses (0.01-0.5 mg), and traditional low doses (1-4.5 mg). If you're highly sensitive, starting at 0.5 mg or lower and titrating very slowly may help. Discuss options with your prescriber. Q7: Does it matter which compounding pharmacy I use? Some people report differences between pharmacies. If you're sensitive, you might try a formulation without silica or other common fillers. There isn't definitive research on this, but some individuals with MCAS or sensitivities notice improvements with cleaner formulations. Q8: Is it normal to feel worse before feeling better? Some people experience a brief adjustment period with mild side effects that resolve. However, feeling significantly worse that doesn't improve over 2-4 weeks isn't necessarily "normal"—it may mean the dose is too high for you. Listen to your body. Q9: What if LDN just doesn't work for me? Research suggests about one-third of people don't respond to standard LDN therapy. This isn't a personal failure—it may mean your condition works through different pathways, or your endorphin reserves are depleted. Some people try again successfully later after addressing other health factors. Q10: I have POTS, hEDS, or MCAS. Any special considerations? These complex conditions often require extra care. Start at very low doses and titrate extremely slowly. For MCAS, LDN alone may not be sufficient—complementary treatments like mast cell stabilizers are sometimes added. Work closely with a provider experienced in these conditions. Part 2: Comprehensive Guide This section provides in-depth information based on clinical experience and published research. Remember, everyone's journey with LDN is unique. Understanding How People Respond to LDN One of the most important things to understand is that not everyone responds to LDN in the same way. Clinical experience and research suggest that people generally fall into three categories: Category 1: LDN Works Well on Its Own For some people, LDN alone produces meaningful and sustained improvement. These individuals typically have adequate baseline endorphin reserves, moderate symptom severity, and good overall functional capacity. Research in fibromyalgia has shown response rates around 57-65%, with some studies demonstrating significant pain reduction compared to placebo (Younger et al., 2013; Toljan & Vrooman, 2023). Category 2: LDN Helps, But Isn't Enough Alone In more complex situations, LDN plays an important supporting role but may not achieve the full results someone is hoping for on its own. Conditions that often fall into this category include mast cell activation syndrome (MCAS), Long COVID, chronic inflammatory response syndrome (CIRS), and complex regional pain syndrome. In these cases, LDN may calm the immune system enough to make other treatments more effective and better tolerated (Kim, 2025). Category 3: Non-Responders Some people simply don't respond to LDN at any dose. This may relate to severely depleted endorphin reserves, genetic variations in opioid receptor function, or conditions that aren't primarily mediated by the pathways LDN affects. If you've given LDN a thorough trial without benefit, this doesn't mean you've failed—it may simply mean LDN isn't the right tool for your particular situation. The Endorphin Reserve Concept A key concept in understanding LDN therapy is what clinicians call "endorphin reserve." LDN works partly by temporarily blocking opioid receptors, which triggers your body to produce more endorphins. But if your body's endorphin-producing capacity is already depleted from prolonged illness, this mechanism may not work as expected. Healthcare providers experienced with LDN often assess functional capacity to estimate endorphin reserve. They may ask about duration of illness, sleep quality, energy levels, recovery time from setbacks, and ability to perform daily activities. People with very low functional capacity often need a much gentler approach to starting LDN (Kim, 2025). Dosing Strategies: One Size Does NOT Fit All This is perhaps the most important section for our community members who are struggling with side effects. Standard Dosing The commonly cited protocol of starting at 1.5 mg and working up to 4.5 mg over 2-4 weeks works well for people with moderate illness and good functional capacity. However, many people in health support communities like ours have more complex situations that require a different approach. Low and Ultra-Low Dosing The LDN Research Trust recognizes three dosing categories: ultra-low dose (microgram range, 1-2 mcg), very-low dose (0.01-0.5 mg daily), and the traditional low dose (1-4.5 mg, sometimes up to 10 mg). At very low doses, naltrexone may work through different mechanisms, potentially acting more gently on the system through a phenomenon called hormesis (LDN Research Trust, 2024). For people who are severely ill, have low functional capacity, or are highly sensitive, starting at 0.5 mg or even lower and increasing very slowly may be essential. Some sensitive individuals may need 2-4 weeks between dose increases, while the most sensitive may need 1-3 months between adjustments. This is a marathon, not a sprint. When Side Effects Persist at Low Doses If you're experiencing persistent side effects even at very low doses, this may indicate that your endorphin reserves are significantly depleted. Options include dropping to an even lower dose, extending the time between dose increases, or discussing with your healthcare provider whether LDN is appropriate for your current situation. Sometimes stepping away and addressing other aspects of health first allows people to try LDN again successfully later. Morning vs. Night: Finding What Works for You The timing question comes up constantly in our group, and for good reason—it can make a significant difference in tolerability. Nighttime dosing is traditionally recommended because LDN's brief opioid receptor blockade coincides with the body's natural endorphin release during sleep. Many people do well with this approach. However, insomnia and vivid dreams are among the most commonly reported side effects, and taking LDN at night can make these worse for some people. Morning dosing works better for those who experience sleep disruption. Some people report feeling drowsy or "out of it" when first switching to morning dosing, but this often improves as the body adjusts. There's no definitive research saying one time is universally better—it's about finding what works for your body. If nighttime dosing is causing severe insomnia, switching to morning is absolutely worth trying. Give any timing change at least a week or two before deciding if it's working. Common Side Effects and What They May Mean Side Effect What It May Indicate Suggested Approach Insomnia / vivid dreams Common with nighttime dosing Try morning dosing; may improve with time Headaches Adjustment period or dose too high Often resolves in 1-2 weeks; reduce dose if severe Fatigue / drowsiness Body adjusting; may indicate dose sensitivity Consider timing change; reduce dose if persistent Irritability / mood changes Possible dose sensitivity Reduce dose; ensure adequate rest Nausea / GI upset Common early effect Take with food; usually improves Vertigo / dizziness May indicate dose too high Reduce dose; titrate more slowly Increased pain (temporary) Some experience initial flare May resolve; discuss with provider if persists Most side effects are temporary and resolve within the first few weeks. However, if side effects persist or worsen despite dose adjustments, this is important information to share with your healthcare provider. When You Initially Tolerated LDN But Now Can't This is a pattern we see repeatedly in our community, and it can be deeply frustrating. You started LDN without problems, built up to a certain dose, and then symptoms appeared that get worse the longer you stay on it—even when you drop back down. Several things may explain this pattern. First, LDN's effects are cumulative over time, so what your body tolerated at first may become too much as levels build. Second, your underlying condition may have changed, affecting how you respond to LDN. Third, there may be interactions with other factors in your health that weren't present initially. If you've tried reducing the dose, taking breaks, and using the every-other-day method without success, it may be time to have a candid conversation with your prescriber about whether to discontinue—at least for now. Stopping LDN is not a failure. Some people return to it successfully later when other aspects of their health have been addressed. Should I Power Through Side Effects or Reduce My Dose? This is one of the most common questions we receive, and the answer depends on the severity and type of side effects. Mild, tolerable side effects (slight sleep changes, mild headache, vivid but not disturbing dreams) often resolve within 1-2 weeks as your body adjusts. If the side effects aren't significantly impacting your quality of life, it may be reasonable to stay at your current dose and give it more time. Moderate to severe side effects (significant insomnia, severe headaches, marked irritability, vertigo, blurred vision) are signals from your body that the current dose is too much. In these cases, reducing the dose or pausing is generally the wiser choice. There's no benefit to "pushing through" if it means feeling miserable. A practical approach: if side effects are getting progressively worse rather than improving, back off. If they're stable or slowly improving, you might give it more time. Special Considerations for POTS, hEDS, and MCAS Many members of our community are managing complex overlapping conditions like postural orthostatic tachycardia syndrome (POTS), hypermobile Ehlers-Danlos syndrome (hEDS), and mast cell activation syndrome (MCAS). These conditions often require extra care when starting LDN. For MCAS in particular, LDN may be helpful but often isn't sufficient on its own. Clinical protocols sometimes combine LDN with mast cell stabilizers like ketotifen or cromolyn sodium (Weinstock et al., 2018). If you have MCAS and are struggling with LDN tolerance, discussing these complementary approaches with your healthcare provider may be worthwhile. People with these conditions often benefit from starting at the lowest possible doses and titrating extremely slowly—sometimes over many months rather than weeks. Does the Compounding Formulation Matter? Some community members report significant differences in how they tolerate LDN from different compounding pharmacies or with different inactive ingredients (excipients). While there isn't robust research on this topic, clinical experience suggests that some people are sensitive to fillers like silica, certain dyes, or other additives. If you're highly sensitive or have MCAS, working with a compounding pharmacy that can prepare LDN with minimal excipients may be worth exploring. Common requests include formulations without silica, dye-free preparations, and hypoallergenic fillers. When to Consider Stopping LDN LDN isn't right for everyone, and recognizing when it's not working is just as important as giving it a fair trial. Consider discussing discontinuation with your healthcare provider if: side effects persist despite multiple dose adjustments and timing changes, you've tried for several months without any perceived benefit, side effects significantly outweigh any benefits, or your symptoms are progressively worsening on the medication. Stopping LDN is generally straightforward since it doesn't cause physical dependence. Some people notice temporary changes when stopping, but these typically resolve within a few days. A Final Word of Support Managing chronic health conditions is challenging, and trying to optimize LDN therapy can feel like solving a puzzle with many pieces. Please remember that your experience is valid, even if it doesn't match what others describe. What works beautifully for one person may not work for another, and that's okay. Always work with a healthcare provider who understands LDN and can help guide your decisions. This community is here to share experiences and support each other, but personalized medical guidance is essential. Be patient with yourself. Be willing to adjust. And know that whether LDN ends up being part of your health toolkit or not, you're on a path toward understanding your body better. LDN Support Group About the Author: Dr. Kim Dr. Yoon Hang "John" Kim is a board-certified integrative medicine physician with over 20 years of clinical experience. He completed his integrative medicine fellowship at the University of Arizona under Dr. Andrew Weil and holds certifications in preventive medicine, medical acupuncture, and integrative/holistic medicine. Through his telemedicine practice, Dr. Kim specializes in using LDN (Low Dose Naltrexone) to treat autoimmune conditions, chronic pain, integrative oncology, and complex conditions, including fibromyalgia, chronic fatigue, MCAS, and mold toxicity. He is the author of three books and more than 20 articles, and has helped establish integrative medicine programs at institutions nationwide. Professional: www.yoonhangkim.com Clinical: www.directintegrativecare.com This document is for educational purposes only and does not constitute medical advice. Individual results vary. Please consult your healthcare provider for personalized guidance. References Bruun, K. D., Christensen, R., Amris, K., et al. (2021). Low-dose naltrexone for the treatment of fibromyalgia: Protocol for a double-blind, randomized, placebo-controlled trial. Trials, 22(1), 804. https://doi.org/10.1186/s13063-021-05804-6 Kim, Y. H. (2018). Ultra low dose naltrexone, micro dosing [Conference presentation]. LDN Research Trust 2018 Conference. Kim, Y. H. (2025). Low-dose naltrexone primer: A clinical guide to optimizing LDN therapy. Direct Integrative Care. https://www.directintegrativecare.com LDN Research Trust. (2024). Dosing information for prescribers. https://ldnresearchtrust.org Toljan, K., & Vrooman, B. (2023). Efficacy of low-dose naltrexone and predictors of treatment success or discontinuation in fibromyalgia and other chronic pain conditions. Biomedicines, 11(4), 1087. https://doi.org/10.3390/biomedicines11041087 Weinstock, L. B., Brook, J. B., Myers, T. L., & Goodman, B. (2018). Successful treatment of postural orthostatic tachycardia and mast cell activation syndromes using naltrexone, immunoglobulin and antibiotic treatment. BMJ Case Reports, bcr2017221405. https://doi.org/10.1136/bcr-2017-221405 Yang, J., Shin, K. M., Do, A., et al. (2023). The safety and efficacy of low-dose naltrexone in patients with fibromyalgia: A systematic review. Journal of Pain Research, 16, 1017-1023. https://doi.org/10.2147/JPR.S397456 Younger, J., Noor, N., McCue, R., & Mackey, S. (2013). Low-dose naltrexone for the treatment of fibromyalgia: Findings of a small, randomized, double-blind, placebo-controlled, counterbalanced, crossover trial. Arthritis & Rheumatism, 65(2), 529-538. https://doi.org/10.1002/art.37734 Younger, J., Parkitny, L., & McLain, D. (2014). The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain. Clinical Rheumatology, 33(4), 451-459. https://doi.org/10.1007/s10067-014-2517-2

An Evidence-Graded Review of Over-the-Counter Botanicals and the Two FDA-Approved Prescription Options Yoon Hang Kim, MD, MPH Board-Certified in Preventive Medicine | Integrative & Functional Medicine Physician Medical Disclaimer: This article is for educational and informational purposes only. It does not constitute medical advice, diagnosis, or treatment, and it is not a substitute for individualized care. Supplements and prescription medications carry real risks and interactions. Do not start, stop, or change any therapy without consulting a qualified healthcare provider who knows your full history. The honest headline first: for the great majority of over-the-counter libido products marketed to women, the evidence that they outperform a placebo is thin, inconsistent, or absent. Most have never been tested in a rigorous randomized trial, and where trials exist they are usually small, short, and industry-funded. A handful of ingredients do show a real—though modest—signal. And the two prescription medications approved for low desire have the strongest data of anything in this space, yet still deliver effect sizes most clinicians would call small. None of that means "nothing works." It means the useful question is rarely which bottle—it is why has desire changed, and what is actually driving it. This review walks through that reasoning first, then grades the ingredients one by one against what the published literature does and does not support. Start With the Differential, Not the Supplement Aisle Low sexual desire is a symptom, not a diagnosis. Before any botanical is worth considering, the more productive step is to look for a treatable driver. In clinical practice these cluster into five buckets: Hormonal shifts — perimenopause and menopause, low testosterone, the postpartum period, thyroid dysfunction, PCOS, and hormonal contraception (which lowers free testosterone in some women). Medications — SSRIs and SNRIs are the classic culprits; some antihypertensives, antipsychotics, and hormonal agents also blunt desire. Medical conditions — diabetes, cardiovascular disease, chronic pain and fatigue, and genitourinary changes such as vaginal dryness or atrophy that make sex uncomfortable. Psychological factors — depression, anxiety, chronic stress, body-image concerns, and a history of trauma. Relationship and lifestyle factors — sleep debt and fatigue, alcohol, relationship conflict, and simple lack of unpressured time and communication. When one of these is the real driver, the supplement question becomes secondary—treating the cause (adjusting a medication, addressing atrophy, treating depression, protecting sleep) tends to do far more than any capsule. Hypoactive sexual desire disorder (HSDD), the formal diagnosis, requires that low desire be persistent and personally distressing, and that other explanations have been reasonably excluded. How to Read the Evidence: Effect Size and the Placebo Problem Two ideas make the rest of this article interpretable. First, effect size (Cohen's d) describes how large a treatment's benefit is beyond placebo: roughly 0.2 is small, 0.5 medium, and 0.8 large. Second, the placebo response in sexual-function trials is unusually high—women in placebo arms routinely report meaningful improvement, because expectation, attention, and simply focusing on intimacy all have genuine effects. Any product's real-world value is only the slice above that placebo response, which is why so many "it worked for me" reports do not survive a controlled trial. Most female sexual-function trials measure outcomes with the Female Sexual Function Index (FSFI) and the Female Sexual Distress Scale (FSDS). Keep those two anchors—effect size and the placebo curve—in mind as we go. The Prescription Options: Best Data, Still Modest Flibanserin (Addyi) A daily oral medication acting on serotonin and dopamine pathways in the brain, approved for acquired, generalized HSDD in premenopausal women. Across the pivotal trials, the effect versus placebo landed in the small range—improvements in desire and reductions in distress with effect sizes around 0.3 to 0.4—and a 2016 systematic review and meta-analysis concluded the benefit amounted to roughly half of one additional satisfying sexual event per month over placebo. The FDA's own review described the average treatment effect as small while noting some women found it clinically meaningful. The safety caveats are not trivial: flibanserin can cause central-nervous-system depression, and this risk rises sharply with alcohol and with drugs that raise its blood levels. Bremelanotide (Vyleesi) An on-demand injectable melanocortin-receptor agonist, self-administered before anticipated activity, also approved for premenopausal HSDD. In the RECONNECT phase 3 trials, it significantly improved desire and reduced distress versus placebo, again with small effect sizes (roughly 0.3 relative to placebo). Nausea is common, and transient blood-pressure elevation means it is avoided in women with uncontrolled hypertension or established cardiovascular disease. The takeaway is not that these drugs fail—they have the most rigorous evidence base in the field—but that even the best-studied options move the needle modestly. That reframes expectations for anything sold without a prescription. The Botanicals and Nutraceuticals, Graded The table below sorts the common ingredients by the strength and consistency of their human trial evidence for female desire or sexual function, not by popularity or marketing. "Reasonable signal" still means small, short trials—it is a relative grade within a low-evidence field. Tier Ingredient & what the trials show Best-fit context Most consistent signal Saffron, ashwagandha, and a tribulus RCT each showed FSFI improvement vs placebo in randomized trials. Maca helped orgasm/arousal chiefly in peri- and postmenopausal women and in SSRI-induced dysfunction. Menopausal transition; SSRI-associated low desire Modest / context-dependent L-arginine combination products (e.g., ArginMax) improved self-reported desire across menopausal status. Fenugreek extract (Libifem) showed benefit in one RCT. Chasteberry has a small signal in postmenopausal women. Women wanting a lower-risk first step Mixed / inconclusive Ginseng, ginkgo. Red clover has solid evidence for hot flushes but only indirect, weak data for desire itself. Effects are inconsistent across studies. Not reliable as a primary strategy Evidence points the other way Oral DHEA: the best randomized trial in postmenopausal women with low libido found no significant benefit over placebo at 50 mg/day, with androgenic side effects (acne, hair growth). Often listed as "supported"—the controlled data don't back that for oral DHEA and low desire. Not supported for this use A closer look at the standouts Saffron (Crocus sativus). Randomized, placebo-controlled trials—including in women with fluoxetine-induced sexual dysfunction—have shown improvement in FSFI scores, and a meta-analysis supports a benefit across sexual-function domains. Among botanicals, this is some of the more reproducible signal. Ashwagandha (Withania somnifera). A placebo-controlled RCT in women with low FSFI scores found significant gains in total FSFI, arousal, lubrication, orgasm, and satisfaction. Plausibly works partly through stress and cortisol pathways rather than hormones directly. Maca (Lepidium meyenii). A systematic review called the overall evidence limited, but the signal is strongest in specific groups: menopausal women, and women with SSRI-induced dysfunction, where a small trial showed benefit concentrated in postmenopausal participants. Notably, it does not appear to raise testosterone. Tribulus terrestris. A randomized, double-blind trial in women with HSDD reported significant FSFI improvement over four weeks. Encouraging but short, and single-trial evidence should be held loosely. L-arginine combinations. Products combining L-arginine with ginseng, ginkgo, and other botanicals (ArginMax) improved self-reported desire and satisfaction across menopausal status in company-associated trials; a later systematic review found L-arginine-based formulas the best-studied of this category, though blinding and funding limit confidence. DHEA—the honest correction. Oral DHEA is frequently listed among "ingredients with support," but the strongest randomized trial in postmenopausal women with low libido found no significant improvement over placebo, while causing androgenic side effects. (A separate, FDA-approved intravaginal form, prasterone, is used for painful sex from vaginal atrophy—a different problem than low desire.) Who Might Reasonably Try Them—And Who Should Not May be reasonable candidates Peri- and postmenopausal women whose desire change tracks with hormonal transition, once atrophy and other drivers are addressed. Women with no identifiable treatable cause who want a lower-risk first step before, or alongside, discussing prescription options with a clinician. Women with SSRI-associated low desire, where saffron and maca have the most relevant trial data—though adjusting the antidepressant with the prescriber is often the higher-yield move. Should generally avoid, or proceed only with medical oversight Anyone pregnant or breastfeeding. Women on blood thinners, or with uncontrolled cardiovascular disease. Women with hormone-sensitive cancers (breast, uterine), given phytoestrogenic ingredients such as red clover. Women with bipolar disorder or a seizure disorder, and those taking MAOIs. Women taking SSRIs, insulin, or other medications with meaningful interaction potential—coordinate first. Anyone approaching surgery (bleeding and anesthesia interactions). Anyone already taking flibanserin, which interacts dangerously with alcohol and can be affected by botanicals such as ginkgo and St. John's wort. The Clinical Bottom Line Libido supplements are best understood as a low-probability, generally-low-risk experiment—reasonable to try in the right person, but not a substitute for finding the actual driver of low desire. If a specific cause exists, treating it is almost always more effective than any capsule. If a woman wants to try a supplement, saffron and ashwagandha have the most defensible evidence, maca is worth considering in the menopausal or SSRI context, and oral DHEA is the one commonly-promoted ingredient the controlled data do not support for this purpose. And because "natural" is not the same as "inert," the safety and interaction screen above matters as much as the efficacy question. If you would like a personalized, evidence-based evaluation of low desire—including the hormonal, medication, and lifestyle contributors that supplements can't fix—my integrative practice is at www.directintegrativecare.com. Selected References 1. Kingsberg SA, Clayton AH, Portman D, et al. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstet Gynecol. 2019;134(5):899–908. 2. Jaspers L, Feys F, Bramer WM, et al. Efficacy and Safety of Flibanserin for the Treatment of Hypoactive Sexual Desire Disorder in Women: A Systematic Review and Meta-analysis. JAMA Intern Med. 2016;176(4):453–462. 3. U.S. FDA, Center for Drug Evaluation and Research. Flibanserin (Addyi) Summary Review, NDA 022526. 2015. 4. Kashani L, Raisi F, Saroukhani S, et al. Saffron for treatment of fluoxetine-induced sexual dysfunction in women: randomized double-blind placebo-controlled study. Hum Psychopharmacol. 2013;28(1):54–60. 5. Ajgaonkar A, Jain M, Debnath K. Efficacy and Safety of Ashwagandha (Withania somnifera) Root Extract for Improvement of Sexual Health in Healthy Women: A Prospective, Randomized, Placebo-Controlled Study. Cureus. 2022;14(10):e30787. 6. Dording CM, Schettler PJ, Dalton ED, et al. A Double-Blind Placebo-Controlled Trial of Maca Root as Treatment for Antidepressant-Induced Sexual Dysfunction in Women. Evid Based Complement Alternat Med. 2015;2015:949036. 7. Shin BC, Lee MS, Yang EJ, Lim HS, Ernst E. Maca (L. meyenii) for improving sexual function: a systematic review. BMC Complement Altern Med. 2010;10:44. 8. Akhtari E, Raisi F, Keshavarz M, et al. Tribulus terrestris for treatment of sexual dysfunction in women: randomized double-blind placebo-controlled study. Daru. 2014;22(1):40. 9. Ito TY, Trant AS, Polan ML. A double-blind placebo-controlled study of ArginMax, a nutritional supplement for enhancement of female sexual function. J Sex Marital Ther. 2001;27(5):541–549. 10. Ito TY, Polan ML, Whipple B, Trant AS. The enhancement of female sexual function with ArginMax among women differing in menopausal status. J Sex Marital Ther. 2006;32(5):369–378. 11. Systematic Review of l-Arginine for the Treatment of Hypoactive Sexual Desire Disorder and Related Conditions in Women. Pharmacy (Basel). 2021;9(2):71. 12. Panjari M, Bell RJ, Jane F, et al. A randomized trial of oral DHEA treatment for sexual function, well-being, and menopausal symptoms in postmenopausal women with low libido. J Sex Med. 2009;6(9):2579–2590. 13. Kanadys W, Barańska A, Błaszczuk A, et al. Evaluation of Clinical Meaningfulness of Red Clover Extract to Relieve Hot Flushes and Menopausal Symptoms in Peri- and Post-Menopausal Women: A Systematic Review and Meta-Analysis. Nutrients. 2021;13(4):1258. About Dr. Kim Dr. Yoon Hang "John" Kim is a board-certified physician with more than 20 years of experience in integrative and functional medicine. He completed a fellowship under Dr. Andrew Weil at the University of Arizona and holds certifications in preventive medicine, medical acupuncture, and integrative and holistic medicine. He specializes in low-dose naltrexone (LDN), autoimmune conditions, chronic pain, integrative oncology, fibromyalgia, chronic fatigue syndrome, mast cell activation syndrome (MCAS), and mold toxicity. He is the author of 3 books and more than 20 peer-reviewed articles. Professional: www.yoonhangkim.com | Clinical: www.directintegrativecare.com

Low Dose Naltrexone in San Antonio: Why It Works, and Why Dr. Kim Yoon Hang Kim, MD, MPH Board-Certified in Preventive Medicine | Integrative & Functional Medicine Physician Living with a chronic condition can feel like working through a to-do list that never quite ends. You try a medication, a symptom quiets down for a while, and the thing underneath it never really moves. If that sounds familiar, Low Dose Naltrexone — usually just called LDN — is worth understanding, because it starts from a different place. Instead of masking a symptom, it asks the body to recalibrate. I've spent more than twenty years practicing integrative and functional medicine, and I lead one of the largest online LDN education communities anywhere. Let me walk you through what LDN is, why so many people here in San Antonio are asking about it, and what makes the care model different. What LDN Actually Does Naltrexone was first approved at high doses — around 50 mg — to treat alcohol and opioid dependence. LDN uses a small fraction of that, typically 1 to 4.5 mg once daily. At that low dose, it behaves in a completely different way. Research suggests it briefly and gently blocks opioid receptors, which prompts the body to raise its own endorphin levels and to calm an overactive inflammatory response in the nervous system, partly by modulating a receptor called Toll-like receptor 4 (Toljan & Vrooman, 2018). Reviews of the chronic-pain literature describe LDN as acting less like a painkiller and more like a novel anti-inflammatory that quiets the glial cells of the central nervous system (Younger, Parkitny & McLain, 2014). A useful way to picture it: LDN doesn't drown out the signal — it helps retune the system that keeps sending it. Why People in San Antonio Are Asking About It The interest isn't hype. LDN is inexpensive, taken once a day at bedtime, and generally well tolerated, which makes it appealing to people who've grown wary of medications that trade one problem for another. What it does require is a physician who understands the nuance — the right starting dose, how to titrate over time, how it fits alongside the rest of your health picture, and where a compounding pharmacy comes in. That's exactly where the choice of provider matters. Why Dr. Kim Here's the honest differentiator. Plenty of clinics can write an LDN prescription. Far fewer have spent years living inside the LDN world. I founded and lead an online LDN community with more than 9,000 members, I've written two books on LDN, and I've watched this therapy help real people across a wide range of conditions. That depth changes the quality of the conversation you and I get to have. How the practice is built matters just as much. Care through www.directintegrativecare.com is membership-based and insurance-free by design — which means appointments aren't rushed, and the plan is genuinely yours rather than a template. We start by understanding your full history and looking for root causes, not just the loudest symptom. When LDN is a fit, it becomes one carefully chosen piece of a larger, personalized plan. Conditions LDN May Help LDN has shown the most promise in conditions that involve immune dysregulation and inflammation. In published reports and reviews, that includes: Autoimmune conditions such as multiple sclerosis Fibromyalgia and other chronic pain syndromes Chronic fatigue syndrome Inflammatory bowel conditions, including Crohn's disease Complex regional pain syndrome LDN isn't a cure, and it isn't right for everyone. But for the right person, it can be a meaningful part of feeling like themselves again. What to Expect We begin with a thorough consultation — your history, your goals, and whether LDN makes sense for you. If it does, we typically start low (often around 1.5 mg at bedtime) and adjust gradually. We follow up, track your response, and fine-tune. Some people notice vivid dreams early on; these usually settle. Benefits tend to build over weeks to months, so patience and communication are part of the process. Learn More: Books by Dr. Kim If you'd like to go deeper, I've written two books on Low Dose Naltrexone, both available on Amazon: The Low Dose Naltrexone (LDN) Primer: 2026 Edition — a 133-page, plain-language guide for anyone new to LDN, covering how it works, what to expect, and its use in conditions such as fibromyalgia, Long COVID, and Hashimoto's thyroiditis. LDN for Clinicians — a comprehensive clinical reference for practitioners who want to understand and prescribe LDN with confidence. Taking the Next Step If you're ready to explore a root-cause approach to a chronic condition — and to work with a physician who knows LDN inside and out — I'd be glad to help. You can learn more and request a consultation at www.directintegrativecare.com. Your body has a real capacity to heal. Sometimes it just needs the right key. In health, Yoon Hang Kim, MD, MPH About Dr. Kim Dr. Yoon Hang “John” Kim is a board-certified physician with more than 20 years of experience in integrative and functional medicine. He completed a fellowship in integrative medicine under Dr. Andrew Weil at the University of Arizona and holds board certifications in Preventive Medicine and Integrative & Holistic Medicine, along with medical acupuncture training. He specializes in Low Dose Naltrexone (LDN), autoimmune conditions, chronic pain, integrative oncology, fibromyalgia, chronic fatigue syndrome, mast cell activation syndrome (MCAS), and mold toxicity. He is the author of 3 books and more than 20 peer-reviewed articles. Professional: www.yoonhangkim.com | Clinical: www.directintegrativecare.com References Younger J, Parkitny L, McLain D. The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain. Clin Rheumatol. 2014;33(4):451–459. Toljan K, Vrooman B. Low-Dose Naltrexone (LDN)—Review of Therapeutic Utilization. Med Sci (Basel). 2018;6(4):82.

Why Choose Yoon Hang Kim, MD, MPH for Functional Medicine in San Antonio Board-Certified in Preventive Medicine | Integrative & Functional Medicine Physician www.directintegrativecare.com If you have been searching for a functional medicine doctor in San Antonio, you have probably noticed that every clinic's website sounds the same: root cause, personalized care, advanced testing. Those are the right words — but words alone do not tell you whether a provider will actually deliver the depth of expertise, accessibility, and sustained partnership your health requires. This post explains why Dr. Yoon Hang Kim's membership-based, insurance-free practice stands apart from the crowd — and why a concierge model may be exactly what chronic-illness care demands. Table of Contents 1. The Problem with the Standard Functional Medicine Search 2. Who Is Yoon Hang Kim, MD, MPH? 3. The Membership Model: Why It Matters 4. Market-Rate Pricing, Far Beyond Market-Rate Access 5. Telemedicine Reach Across Multiple States 6. Comparing Care Models 7. Who Benefits Most from This Practice? 8. What Sets This Apart in San Antonio 9. Key Takeaways 10. Frequently Asked Questions 11. Taking the Next Step The Problem with the Standard Functional Medicine Search A quick search for "functional medicine San Antonio" returns dozens of results. Many are large multi-provider clinics running high-volume schedules. Others are cash-pay practices that still rely on per-visit billing, meaning your access to your doctor depends on whether you can book the next available slot — often weeks out. In both models, the relationship is transactional: you buy an appointment, you receive a service, and between visits you are largely on your own. For people with complex, overlapping conditions — autoimmune disease, mast cell activation syndrome (MCAS), chronic fatigue, mold toxicity, POTS, or fibromyalgia — that episodic model falls short. These conditions do not wait for your next scheduled appointment. Questions surface between visits, lab results need interpretation in real time, and treatment plans require continuous fine-tuning. The gap between what clients need and what most practices deliver is where Dr. Kim's model fills a critical void. Who Is Yoon Hang Kim, MD, MPH? Dr. Kim brings more than 20 years of clinical experience in integrative and functional medicine. His training includes an Osher Fellowship under Dr. Andrew Weil at the University of Arizona Center for Integrative Medicine — widely considered the gold standard in integrative medical education. He holds board certifications in Preventive Medicine and Integrative & Holistic Medicine, a medical acupuncture certification from UCLA, and IFM (Institute for Functional Medicine Scholarship Recipient. His clinical expertise spans complex chronic illness including autoimmune conditions, MCAS, mold toxicity and CIRS, chronic fatigue syndrome, fibromyalgia, POTS, integrative oncology, and low-dose naltrexone (LDN) therapy. Dr. Kim is an internationally recognized authority on LDN, having authored multiple books on the subject — including the clinician textbook LDN for Clinicians, Researchers, and Empowered Patients — published over 20 peer-reviewed articles, and founded the LDN Support Group, a community of more than 9,000 members. He has previously served as Medical Director of Integrative Oncology at Miami Cancer Institute and as Director of the Integrative Medicine Program at the University of Kansas Medical Center. Dr. Kim's depth of training, clinical volume, and academic contributions place him among the most credentialed integrative and functional medicine physicians practicing in Texas today. The Membership Model: Why It Matters The practice at www.directintegrativecare.com operates on a membership model — sometimes called direct primary care or concierge medicine — rather than conventional fee-for-service billing. Here is what that means in practice: ● Capped panel size. Dr. Kim limits his active client panel to 99 individuals. A typical primary care physician manages 2,000 to 3,000 clients; most concierge practices cap between 300 and 600. A smaller panel translates directly into longer visits, faster responses, and a physician who actually knows your case — not just your chart. ● Predictable monthly investment. Rather than being surprised by per-visit charges or unpredictable insurance co-pays, members pay a flat monthly fee that covers ongoing access to Dr. Kim. Full details are available on the fee schedule. This transparency eliminates the financial uncertainty that discourages many people from seeking the care they need. ● Insurance-free by design. The practice does not bill insurance. While that may sound counterintuitive, it is actually liberating — for both the client and the physician. Insurance dictates visit length, limits which tests can be ordered, and often delays referrals. Removing the insurance middleman means Dr. Kim can spend the time a case requires, order the labs a case demands without payer restrictions, and pursue the treatment strategy that serves the client rather than the payer. ● Continuous access, not episodic care. Membership means the relationship does not end when the visit does. Clients have ongoing communication access for questions, lab interpretation, and care coordination. This continuity is especially critical for conditions that fluctuate — like MCAS flares, hormonal shifts, or post-infectious syndromes — where waiting weeks for a follow-up appointment can mean unnecessary suffering. Market-Rate Pricing, Far Beyond Market-Rate Access Most concierge and membership practices limit their panels to somewhere between 300 and 600 clients. Even practices charging well above the national median typically cap between 200 and 400. Dr. Kim caps his panel at 99. That is the number that matters. Membership pricing at this practice sits within the ordinary national range for concierge and direct-care medicine — roughly $250 to $350 per month, with current tiers detailed on the fee schedule. What is not ordinary is what that fee buys: a panel three to six times smaller than the concierge norm. Fewer clients per physician is the structural variable that determines whether "personalized care" is a slogan or a daily reality. This is a deliberate philosophical choice. Dr. Kim's guiding principle is that sustainable health outcomes require a long-term partnership, not a one-off encounter. Building the practice around a small panel rather than around volume is what allows him to give each client the depth of attention their condition requires — and it is why membership is capped rather than open-ended. Telemedicine Reach Across Multiple States While Dr. Kim is based in San Antonio, the practice is built on a telemedicine-forward model that extends well beyond city limits. Dr. Kim holds active medical licenses in Texas, Iowa, Illinois, Missouri, Georgia, and Florida, enabling him to serve clients across a significant geographic footprint. Whether you are in Houston, Atlanta, Des Moines, or Jacksonville, you can access the same unhurried, membership-based care as someone sitting in Alamo Heights. For individuals outside these states or outside the United States, Dr. Kim also offers Educational Consultation Agreements — structured 30-minute video sessions that provide guidance within appropriate professional boundaries. This means that even if licensure limitations prevent a formal clinical relationship, you are not entirely shut out from Dr. Kim's expertise. Comparing Care Models The table below outlines how this practice differs from the two most common alternatives a San Antonio client is likely to encounter. Feature Insurance-Based Primary Care Typical Concierge Membership (This Practice) Panel size 2,000–3,000 clients 300–600 clients Capped at 99 Visit length 10–15 minutes 30–60 minutes Extended, unhurried Access between visits Phone tag / portal Direct, varies Ongoing direct access Billing model Insurance + copays Membership, often + insurance Flat monthly, insurance-free Care focus Symptom management Enhanced primary care Root-cause, longitudinal Complex chronic illness fit Limited Varies by provider Built for it Who Benefits Most from This Practice? Dr. Kim's practice is not designed to be all things to all people. It is specifically built for individuals who have complex, chronic health challenges and who have often felt failed by conventional medicine. If any of the following resonate, this model may be the right fit: ● You have been through multiple specialists without clear answers or meaningful improvement. ● You have an autoimmune diagnosis — or suspect one — and want a provider who looks beyond immunosuppression as the only strategy. ● You are dealing with MCAS, POTS, mold illness, chronic fatigue, or fibromyalgia and need a physician experienced with these specific conditions. ● You are a cancer survivor or active oncology client seeking integrative support alongside conventional treatment. ● You are interested in LDN therapy and want guidance from one of the foremost clinical experts in the field. ● You value a physician relationship built on partnership and communication, not assembly-line medicine. What Sets This Apart in San Antonio San Antonio has a growing number of integrative and functional medicine providers, and many are doing good work. But there are meaningful differences worth noting: ● Depth of specialization. Many functional medicine practices take a generalist approach — broad wellness optimization. Dr. Kim's practice is oriented toward complex chronic illness, which requires a different clinical skillset, a different testing philosophy, and a different tolerance for diagnostic ambiguity. ● Academic and research foundation. With over 20 peer-reviewed publications, multiple books, and national-level speaking engagements, Dr. Kim's clinical decisions are grounded in evidence — not trends. When he recommends a protocol, it is backed by literature he has personally evaluated and, in many cases, contributed to. ● Panel size discipline. It is easy for a practice to claim "personalized care." It is much harder to enforce the structural constraints — like a 99-client cap — that make personalized care actually possible. This is a practice that has chosen to stay small on purpose. ● Continuity and relationship. In a membership model, Dr. Kim is your physician over months and years, not for a single consultation. He tracks your trajectory, remembers your history, and adjusts your plan as your life and body change. That longitudinal relationship is where the real clinical value lives. Key Takeaways ● Root-cause, longitudinal care. The membership model means a capped panel, direct access, and a physician relationship measured in years, not visits. ● Insurance-free is liberating. Removing the payer removes restrictions on visit length, testing, and treatment strategy. ● Built for complexity. Autoimmune disease, MCAS, POTS, mold illness, integrative oncology, and LDN therapy are core areas of expertise. ● Reach across six states. Telemedicine care in TX, IA, IL, MO, GA, and FL, plus educational consultations for those elsewhere. ● Typical fee, atypical panel. Membership pricing sits in the ordinary concierge range, but the panel is capped at 99 rather than the customary 300 to 600. ● Get started. Call or text (210) 981-6106, or visit www.directintegrativecare.com. Frequently Asked Questions What does the membership include? Membership covers ongoing access to Dr. Kim — extended visits, communication between appointments, lab interpretation, and care coordination — under a flat monthly fee. Specific inclusions by tier are listed on the fee schedule. Do you take insurance? No. The practice is insurance-free by design, which allows Dr. Kim to determine visit length, testing, and treatment based on what your case requires rather than what a payer will authorize. Clients may still use insurance independently for outside labs, imaging, or medications. Can I see Dr. Kim if I live outside Texas? Yes, if you are in Iowa, Illinois, Missouri, Georgia, or Florida, where Dr. Kim is also licensed. For those outside these states or abroad, Educational Consultation Agreements offer a structured way to access his guidance within professional boundaries. How does the cost compare to other concierge practices? Membership here sits within the ordinary national range for concierge and direct-care medicine. The difference is not the price — it is the panel. Most concierge practices carry 300 to 600 clients per physician; Dr. Kim caps at 99. You are paying a typical membership fee for a substantially smaller panel and correspondingly greater access. Current tiers are listed on the fee schedule. How do I get started? Call or text (210) 981-6106, or visit www.directintegrativecare.com to review membership options and begin with a virtual assessment. Taking the Next Step If you are ready to move beyond symptom management and invest in a physician relationship built for the long haul, Dr. Yoon Hang Kim's practice may be the partnership you have been looking for. Call or text (210) 981-6106, or visit www.directintegrativecare.com to review membership options, see the fee schedule, and take the first step toward care designed around you — not around an insurance company's priorities. Disclaimer: This blog post is for educational and informational purposes only and does not constitute medical advice, diagnosis, or treatment. The information provided should not replace a consultation with a qualified healthcare provider. Individual results may vary. If you have questions about your health, please consult a licensed physician. About Dr. Kim Dr. Yoon Hang "John" Kim is a board-certified physician with more than 20 years of experience in integrative and functional medicine. He completed his fellowship training at the University of Arizona Center for Integrative Medicine under Dr. Andrew Weil and holds certifications in preventive medicine, medical acupuncture (UCLA), and integrative & holistic medicine, along with IFM Scholar status. Dr. Kim specializes in low-dose naltrexone (LDN) therapy, autoimmune conditions, chronic pain, integrative oncology, fibromyalgia, chronic fatigue syndrome, mast cell activation syndrome (MCAS), and mold toxicity. He has authored 3 books, published over 20 peer-reviewed articles, and founded the LDN Support Group with more than 9,000 members. Professional: www.yoonhangkim.com | Clinical: www.directintegrativecare.com

How to Approach Your Doctor About Low-Dose Naltrexone (LDN): A Patient's Guide to a Productive Conversation Written and medically reviewed by: Yoon Hang Kim, MD, MPH Board-Certified in Preventive Medicine | Integrative & Functional Medicine Physician www.directintegrativecare.com Disclaimer: This article is intended for educational and informational purposes only and does not constitute medical advice, diagnosis, or treatment. Low-dose naltrexone (LDN) is used off-label for the conditions discussed below; it is not FDA-approved for any of them. All therapeutic decisions, including the use of LDN, should be made in consultation with a qualified healthcare provider who can evaluate individual circumstances. Nothing in this article creates a physician-patient relationship. Last updated: August 2026 The Short Answer If you believe low-dose naltrexone might help your condition, come prepared: bring published evidence, frame your request as a question rather than a demand, and understand why your physician may hesitate. This article gives you the tools to have that conversation — honestly, respectfully, and with the best available evidence in hand. Introduction One of the most common frustrations I hear from patients — in my own practice and through the LDN Support Group community of over 9,000 members — is not about LDN itself. It is about getting their doctor to consider prescribing it. The frustration is understandable. You have done your research. You have read about other patients whose chronic pain, autoimmune symptoms, or fatigue improved. You may have found peer-reviewed studies suggesting benefit for your specific condition. And yet, when you raise it with your physician, the response is often dismissive, noncommittal, or simply "I've never heard of that." This is not necessarily your doctor's fault, and it does not mean LDN is without merit. What it usually reflects is a systemic gap: the published evidence for LDN has grown considerably over the past decade, but it has not yet penetrated most standard medical training. Understanding why that gap exists — and knowing how to bridge it respectfully — is the purpose of this guide. At its core, this is a conversation about shared decision-making: the collaborative process in which patients and physicians bring different knowledge to the same table. You bring your experience of your illness. Your physician brings clinical training and the responsibility to evaluate evidence. Neither party has the full picture alone. The strategies in this article are designed to make that collaboration work [18,19]. Why Many Physicians Hesitate to Prescribe LDN Before preparing your approach, it helps to understand the legitimate reasons a physician might be reluctant. These are real clinical and professional considerations — not excuses — and acknowledging them during your conversation signals that you are an informed patient, not someone pushing a fringe remedy. Unfamiliarity The most common barrier is simply not knowing enough about LDN. Naltrexone is taught in medical school as a 50 mg medication for opioid and alcohol use disorders. The idea that one-tenth of that dose might exert entirely different pharmacological effects — through TLR4 antagonism on microglial cells rather than classical opioid receptor blockade — is counterintuitive [1,2]. A 2022 multisite survey found that the most commonly reported barrier to prescribing naltrexone among non-addiction-trained physicians was unfamiliarity with its therapeutic uses [3]. Only about one in four surveyed prescribers had written a naltrexone prescription in the preceding three months — and that survey examined the standard 50 mg dose, not the low-dose applications [3]. The knowledge gap for LDN is far wider. Off-Label Prescribing Concerns LDN is not FDA-approved for any of the conditions it is commonly used to treat — fibromyalgia, Crohn's disease, multiple sclerosis, chronic pain, autoimmune conditions, or long COVID. This matters to physicians because prescribing something off-label requires confidence in the supporting evidence. Off-label prescribing is entirely legal and common — studies estimate that 21% to 38% of all outpatient prescriptions in the United States are off-label [4,5]. Gabapentin for neuropathic pain, amitriptyline for migraine prevention, and metformin for polycystic ovarian syndrome are all everyday off-label prescriptions most physicians write without hesitation. But when a physician has not reviewed the evidence for a particular off-label use, hesitation is rational, not obstructionist. Compounding Pharmacy Requirements Unlike most medications, LDN cannot be dispensed from a standard pharmacy. Naltrexone is only commercially available as 50 mg tablets (or injectable depot formulations for addiction), so low doses — typically 0.5 to 4.5 mg — must be prepared by a compounding pharmacy. This adds logistical complexity that many physicians have not navigated. Some do not know this pathway exists or how to write a prescription for a compounded medication. Insufficient Large-Scale Trial Evidence Physicians are trained to value randomized controlled trials above all other evidence, and the LDN literature has a real limitation: most positive studies are small. The landmark fibromyalgia pilot enrolled 10 participants [6], the crossover trial included 28 [7], and the Crohn's disease pilot involved 17 [8]. The largest and most rigorous fibromyalgia RCT to date — 99 women randomized to naltrexone or placebo for 12 weeks — did not find LDN superior to placebo on its primary pain endpoint, though adverse events were essentially identical between groups [9]. (That trial used a 6 mg dose, which is above the conventional LDN ceiling of 4.5 mg — a detail the LDN clinical community considers relevant, though it does not erase the result.) A physician who looks at this landscape and says "the evidence is promising but limited" is being honest, not dismissive. Concern About Interactions and Safety Monitoring The most important safety consideration is well-established: naltrexone at any dose blocks opioid receptors and will reduce or eliminate the effectiveness of opioid pain medications. Perioperative guidelines broadly recommend discontinuing oral naltrexone at least 72 hours before elective surgery, and after discontinuation, opioid responses can become unpredictable due to receptor upregulation [10,11]. Any patient taking LDN must carry this information and disclose it proactively to emergency, surgical, and anesthesia teams. This is a safety issue, not a preference. Preparing for the Conversation: What to Bring The difference between a productive conversation and a frustrating one often comes down to preparation. Organized, credible information signals respect for your physician's expertise while giving them the tools they need to evaluate LDN on its merits. Bring Published Evidence — Not Internet Forums Physicians respond to peer-reviewed literature. Anecdotes from Facebook groups, however heartfelt, do not carry clinical weight. Fortunately, the LDN evidence base has matured considerably. The foundational mechanistic review is Younger, Parkitny, and McLain (2014), which established that LDN operates via TLR4 antagonism on microglia — independent of classical opioid receptor effects [1]. Toljan and Vrooman (2018) provide a comprehensive clinical review covering mechanism, dosing, and evidence across multiple conditions [2]. Patten, Schultz, and Berlau (2018) focus specifically on the safety profile, which is consistently favorable [12]. The most recent overview — a 2023 scoping review in Pain Medicine — identified 47 studies across multiple chronic pain conditions [13]. Full citations with PubMed IDs are in the References section; any of these can be printed and handed to your physician. For condition-specific conversations: the strongest RCT data comes from Crohn's disease, where Smith et al. published an open-label pilot showing 67% remission rates [8] followed by a placebo-controlled trial demonstrating improved mucosal healing [14]. In fibromyalgia, earlier trials showed reduced pain severity and decreased pro-inflammatory cytokines [6,7,15], though as noted above, the largest RCT did not confirm superiority over placebo [9]. In multiple sclerosis, a pilot trial showed improvement in mental-health quality-of-life measures [16]. In long COVID and ME/CFS, a 2026 systematic review in BMJ Open found moderate-to-large favorable effect sizes for fatigue, pain, and sleep — while explicitly noting that no randomized controlled trials were identified and rating overall certainty of evidence as low [17]. Present this evidence honestly. The case for LDN is that it has a plausible mechanism, a favorable safety profile, and a growing but still-developing body of clinical evidence. That is a reasonable basis for a conversation — not a guarantee. Consider Gifting the LDN Primer I wrote the Low-Dose Naltrexone (LDN) Primer: 2026 Edition for exactly this situation — a concise, evidence-based introduction that any physician can read in a single sitting. It covers mechanism, conditions where evidence exists, realistic expectations about response rates, dosing, and what LDN cannot do. Chapter 11 includes a sample letter you can bring to your doctor and a practical guide to finding an LDN prescriber. The Primer is available on Amazon in Kindle and paperback: amazon.com/dp/B0GZ9R4667 Gifting the Primer to your physician shifts the dynamic. Instead of asking them to prescribe something they have never heard of, you are handing them a referenced book from a board-certified colleague and asking them to evaluate it on its merits. The book does the educational work so the conversation can focus on whether LDN is appropriate for you. About two-thirds of patients respond meaningfully to LDN; about one-third do not. The Primer names this openly and devotes a full chapter to what to do when standard LDN does not work. That candor is what builds physician trust. For clinicians and researchers seeking deeper discussion, the companion volume — LDN for Clinicians, Researchers, and Empowered Patients: Two Decades of Clinical Observation (2026 Edition) — offers sixteen chapters on pharmacology, evidence, and practical dosing frameworks. Use Free Educational Resources Not everyone wants to purchase a book, and not every physician needs one. The full library of referenced articles at www.ifmsynergy.com is available at no cost. Articles particularly useful for physician conversations include: LDN in Functional Medicine: A Practical Guide — Individualized dosing and clinical integration 15 Teaching Points from the LDN Support Group Pop-Up Live — Evidence-referenced review including the negative fibromyalgia RCT Integrating LDN Into a Multimodal Strategy for Interstitial Cystitis — 35 peer-reviewed references LDN, Emotional Distress, Neuropathy, and Mitochondrial Support — Pairing LDN with complementary strategies These articles include editor's notes where evidence diverges from clinical enthusiasm, negative trial results alongside positive ones, and explicit statements about what remains uncertain. That is the kind of resource a thoughtful physician can trust. How to Frame the Conversation Tone matters as much as content. Here are practical approaches drawn from my experience on both sides of the conversation. Lead With Your Symptoms, Not the Drug Start with what you are experiencing and what has not worked, not with "I want LDN." A physician is far more receptive to: "I have been dealing with [condition] for [duration]. I have tried [treatments X, Y, Z] without adequate improvement. In my research, I came across low-dose naltrexone and wanted to ask whether it might be appropriate for me." The first framing positions you as a partner. Contrast it with: "I read online that LDN can cure [condition] and I want you to prescribe it." The second positions you as someone who has already made the clinical decision and is asking the physician to sign off on it. Acknowledge What You Do Not Know Something like: "I understand the evidence is still developing and that LDN is off-label — I am not asking you to promise it will work, I am asking whether it is reasonable to try." This communicates intellectual honesty and makes the physician more willing to engage. Offer Materials and Time Hand your physician something they can review at their own pace: "I brought this book [or article] that covers the evidence and dosing. Would you be willing to review it and discuss at our next visit?" This removes the pressure of an on-the-spot decision and respects the reality that a 15-minute appointment is not sufficient to evaluate an unfamiliar therapy. Bring the Safety Data One of LDN's strongest arguments is its safety profile. Adverse events across the published literature are consistently mild and typically transient: vivid dreams, mild sleep disturbance, headache, nausea [1,2,12]. In the largest fibromyalgia RCT, adverse event rates were essentially identical between the LDN group (84%) and placebo group (86%) [9]. A physician is more likely to try a therapy with a favorable risk-benefit ratio, even when the efficacy evidence is still developing. If Your Doctor Says No A refusal is not necessarily the end of the conversation. "I'm not comfortable prescribing something I don't know enough about." Respect this — it is honest. Offer the Primer or a review article and ask whether they would be willing to revisit the discussion after reviewing the material. If they say yes, follow up. "There isn't enough evidence." Partly true and partly a matter of perspective. Acknowledge the limitation while noting that the existing evidence — including the 2023 scoping review covering 47 studies [13] and condition-specific RCTs in Crohn's disease [8,14] — has been substantial enough that Stanford, the University of Alabama at Birmingham, and Dartmouth have all launched clinical trials evaluating LDN. The absence of large Phase III trials reflects the economics of generic medications — no pharmaceutical company will fund a $50 million trial for a drug they cannot patent — not a verdict on efficacy. "I don't know how to prescribe it." This is a practical barrier, not a philosophical one. LDN must be obtained from a compounding pharmacy. Typical starting doses are 0.5 to 1.5 mg daily, titrated slowly. The Primer covers prescribing details. The LDN Research Trust (ldnresearchtrust.org) also maintains resources for prescribers. If your physician remains unwilling, consider seeking an integrative or functional medicine physician with LDN experience. The LDN Support Group community is an excellent resource for connecting with knowledgeable prescribers. Calling local compounding pharmacies and asking which physicians in your area prescribe LDN is another practical strategy outlined in Chapter 11 of the Primer. What Not to Do Do not present LDN as a miracle cure. It is not. Overclaiming erodes your credibility and your physician's willingness to engage. Do not self-prescribe. Purchasing naltrexone from unregulated online sources and titrating without medical supervision is unsafe. LDN requires a prescription, a reputable compounding pharmacy, and clinical oversight — particularly for monitoring drug interactions, coordinating perioperative management, and adjusting dosing. Do not threaten or issue ultimatums. "If you won't prescribe this, I'll find someone who will" — even if true — poisons the relationship and confirms every negative assumption about internet-educated patients. Do not conflate your experience with evidence. If you have tried LDN through another provider and it helped, share that as your personal experience, not as proof that it works for everyone. Physicians respect the distinction. A Note About Shared Decision-Making The modern medical literature recognizes shared decision-making as the standard for clinical care [18,19]. This is mainstream medical ethics, not a radical concept. What it means practically: you have the right to bring information, ask questions, and participate in decisions about your care. Your physician has the responsibility to evaluate that information against their clinical knowledge and explain their reasoning. Both parties carry obligations. The patient who refuses to hear "no" is not practicing shared decision-making. Neither is the physician who refuses to hear the question. LDN sits in a space well-suited to shared decision-making: a therapy with a plausible mechanism, a growing evidence base, a favorable safety profile, and enough uncertainty that the patient's values and willingness to try something off-label are legitimately relevant to the clinical decision. Frequently Asked Questions Is it legal for my doctor to prescribe LDN off-label? Yes. Off-label prescribing is entirely legal in the United States and accounts for an estimated 21% to 38% of all outpatient prescriptions [4,5]. Any licensed physician can prescribe naltrexone at any dose for any condition they deem clinically appropriate. Where do I get LDN if my doctor prescribes it? LDN must be obtained from a compounding pharmacy, since naltrexone is only commercially available as 50 mg tablets. Your physician writes a prescription specifying the dose (commonly 0.5–4.5 mg), and the compounding pharmacy prepares it. Many compounding pharmacies ship nationwide. Can I take LDN with my current medications? LDN is contraindicated with opioid medications — naltrexone blocks opioid receptors and will reduce or eliminate opioid analgesia. Patients on opioids must work with their prescriber to discontinue opioids before starting LDN. Most other medications are compatible, but always disclose your full medication list [10,11]. How long does LDN take to work? Response timelines vary. Some patients notice improvement within weeks; others require two to three months. If there is no meaningful response after an adequate trial at the appropriate dose, LDN may not be the right tool for that individual. What if my doctor says no? See the detailed section above. In short: respect their reasoning, offer educational materials, and ask whether they would be willing to revisit the conversation. If they remain unwilling, an integrative or functional medicine physician with LDN experience may be a better fit. Summary Table Topic Key Point Most common physician barrier Unfamiliarity — LDN is not taught in standard medical training Off-label status Legal and routine; 21–38% of all U.S. prescriptions are off-label Strongest condition-specific evidence Crohn's disease (RCTs showing remission and mucosal healing) Broadest evidence survey 47 studies identified across a 2023 scoping review of centralized pain conditions Honest limitation Largest fibromyalgia RCT (6 mg dose) did not find superiority over placebo on primary pain outcome Safety profile Consistently favorable; adverse events mild and typically transient Critical safety note LDN blocks opioid receptors — must disclose to surgical/emergency teams Must be obtained from A compounding pharmacy (not available as a commercial low-dose product) Typical starting dose 0.5–1.5 mg daily, titrated slowly and individualized Response rate Approximately two-thirds respond meaningfully; one-third do not Best resource for physicians LDN Primer: 2026 Edition (Amazon) or free articles at www.ifmsynergy.com Best resource for finding a prescriber LDN Support Group community; local compounding pharmacies #LDN #LowDoseNaltrexone #LDNPrimer #PatientAdvocacy #SharedDecisionMaking #OffLabelPrescribing #IntegrativeMedicine #FunctionalMedicine #ChronicPain #Fibromyalgia #AutoimmuneDisease #CrohnsDisease #LongCOVID #MECFS #MCAS #Neuroinflammation #DrYoonHangKim #IFMSynergy #LDNSupportGroup #EvidenceBasedMedicine References 1. Younger J, Parkitny L, McLain D. The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain. Clin Rheumatol. 2014;33(4):451–459. doi:10.1007/s10067-014-2517-2. PMID: 24526250 2. Toljan K, Vrooman B. Low-dose naltrexone (LDN) — review of therapeutic utilization. Med Sci (Basel). 2018;6(4):82. doi:10.3390/medsci6040082. PMID: 30248938 3. Lenz JG, Kjellgren RW, Hester BD, et al. Assessing naltrexone prescribing and barriers to initiation for alcohol use disorder: a multidisciplinary, multisite survey. Ment Health Clin. 2022;12(3):174–179. doi:10.9740/mhc.2022.06.174. PMID: 35619618 4. Radley DC, Finkelstein SN, Stafford RS. Off-label prescribing among office-based physicians. Arch Intern Med. 2006;166(9):1021–1026. doi:10.1001/archinte.166.9.1021. PMID: 16682577 5. Bradford WD, Turner JL, Williams JW. Off-label use of pharmaceuticals: a detection controlled estimation approach. J Ind Econ. 2018;66(4):866–903. doi:10.1111/joie.12189. 6. Younger J, Mackey S. Fibromyalgia symptoms are reduced by low-dose naltrexone: a pilot study. Pain Med. 2009;10(4):663–672. doi:10.1111/j.1526-4637.2009.00613.x. PMID: 19453963 7. Younger J, Noor N, McCue R, Mackey S. Low-dose naltrexone for the treatment of fibromyalgia: findings of a small, randomized, double-blind, placebo-controlled, counterbalanced, crossover trial assessing daily pain levels. Arthritis Rheum. 2013;65(2):529–538. doi:10.1002/art.37734. PMID: 23359310 8. Smith JP, Stock H, Bingaman S, Mauger D, Rogosnitzky M, Zagon IS. Low-dose naltrexone therapy improves active Crohn's disease. Am J Gastroenterol. 2007;102(4):820–828. doi:10.1111/j.1572-0241.2007.01045.x. PMID: 17222320 9. Due Bruun K, Christensen R, Amris K, et al. Naltrexone 6 mg once daily versus placebo in women with fibromyalgia: a randomised, double-blind, placebo-controlled trial. Lancet Rheumatol. 2024;6(1):e31–e39. doi:10.1016/S2665-9913(23)00278-3. PMID: 38258677 10. Agency for Healthcare Research and Quality (AHRQ) PSNet. A painful medication reconciliation mishap — perioperative naltrexone management. psnet.ahrq.gov 11. Whately Y, et al. Perioperative management of patients on naltrexone. Australian and New Zealand College of Anaesthetists resource. ANZCA 12. Patten DK, Schultz BG, Berlau DJ. The safety and efficacy of low-dose naltrexone in the management of chronic pain and inflammation in multiple sclerosis, fibromyalgia, Crohn's disease, and other chronic pain disorders. Pharmacotherapy. 2018;38(3):382–389. doi:10.1002/phar.2086. PMID: 29377216 13. Rupp A, Young E, Chadwick AL. Low-dose naltrexone's utility for non-cancer centralized pain conditions: a scoping review. Pain Med. 2023;24(11):1270–1281. doi:10.1093/pm/pnad074. PMID: 37302106 14. Smith JP, Bingaman SI, Ruggiero F, et al. Therapy with the opioid antagonist naltrexone promotes mucosal healing in active Crohn's disease: a randomized placebo-controlled trial. Dig Dis Sci. 2011;56(7):2088–2097. doi:10.1007/s10620-011-1653-7. PMID: 21380937 15. Parkitny L, Younger J. Reduced pro-inflammatory cytokines after eight weeks of low-dose naltrexone for fibromyalgia. Biomedicines. 2017;5(2):16. doi:10.3390/biomedicines5020016. PMID: 28536359 16. Cree BA, Kornyeyeva E, Goodin DS. Pilot trial of low-dose naltrexone and quality of life in multiple sclerosis. Ann Neurol. 2010;68(2):145–150. doi:10.1002/ana.22006. PMID: 20695007 17. Byambasuren O, Atkins TJ, Baptista S, Glasziou P, Chakraborty S. Effect of low-dose naltrexone for long COVID: a systematic review and meta-analysis. BMJ Open. 2026;16:e111253. doi:10.1136/bmjopen-2025-111253. 18. Stiggelbout AM, Van der Weijden T, De Wit MPT, et al. Shared decision making: really putting patients at the centre of healthcare. BMJ. 2012;344:e256. doi:10.1136/bmj.e256. PMID: 22286508 19. Elwyn G, Frosch D, Thomson R, et al. Shared decision making: a model for clinical practice. J Gen Intern Med. 2012;27(10):1361–1367. doi:10.1007/s11606-012-2077-6. PMID: 22618581 All references verified against PubMed or publisher records. Citations reflect the strength and limitations of the underlying evidence, including trials with negative as well as positive results. About Dr. Kim Dr. Yoon Hang "John" Kim is a board-certified physician with over 20 years of experience spanning preventive medicine, integrative and functional medicine, medical acupuncture, and integrative holistic medicine. A fellowship-trained graduate of the University of Arizona Center for Integrative Medicine under Dr. Andrew Weil, Dr. Kim specializes in low dose naltrexone (LDN), autoimmune conditions, chronic pain, integrative oncology, fibromyalgia, chronic fatigue syndrome, mast cell activation syndrome (MCAS), and mold-related illness. He is the author of the LDN Primer: 2026 Edition and LDN for Clinicians, Researchers, and Empowered Patients: Two Decades of Clinical Observation (2026 Edition), and has published more than 20 articles in integrative medicine. Professional: www.yoonhangkim.com Clinical: www.directintegrativecare.com Related Reading on IFMSynergy.com Low Dose Naltrexone (LDN) in Functional Medicine: A Practical Guide by Dr. Yoon Hang Kim 15 Teaching Points from the LDN Support Group Pop-Up Live — An Evidence-Referenced Review A Functional Medicine Approach to Interstitial Cystitis: Integrating Low-Dose Naltrexone Into a Multimodal Strategy LDN, Emotional Distress, Neuropathy, Chronic Fatigue Syndrome, and Mitochondrial Support Berkson's ALA/LDN Protocol in Integrative Oncology The Endorphin Depletion Hypothesis in CFS/ME SEO Keywords: How to ask your doctor about LDN, low dose naltrexone prescription, LDN Primer book, Dr Yoon Hang Kim, LDN patient advocacy, off-label prescribing LDN, how to get LDN prescribed, low dose naltrexone doctor, LDN evidence for physicians, ifmsynergy LDN, integrative medicine San Antonio, LDN support group, LDN dosing guide, approach doctor about LDN